Search

Your search keyword '"Lampertico P."' showing total 1,570 results
Start Over Author "Lampertico P."
1,570 results on '"Lampertico P."'

1. Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis

Author

Cornberg, Markus, Hüppe, Dietrich, Sarrazin, Christoph, Ahumada, Adriana, Jorquera Plaza, Francisco, Mariño, Zoe, Otano, Juan Isidro Uriz, Conway, Brian, Myles, Lindsay, Ramji, Alnoor, Abergel, Armand, Asselah, Tarik, Larrey, Dominique, Aghemo, Alessio, Andreoni, Massimo, Gasbarrini, Antonio, Lampertico, Pietro, Persico, Marcello, Villa, Erica, Carmiel, Michal, Chodick, Gabriel, Weil, Clara, Bhagat, Abhi, Bondin, Mark, Butrymowicz, Isabel, Song, Yanna, Semizarov, Dimitri, Sonparote, Sadhana, and Llamas, Cynthia

Published
2024
Full Text
View/download PDF

4. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

Author

Razavi-Shearer, D., Child, H., Razavi-Shearer, K., Voeller, A., Razavi, H., Buti, M., Tacke, F., Terrault, N., Zeuzem, S., Abbas, Z., Aghemo, A., Akarca, U.S., Al Masri, N., Alalwan, A., Blomé, M. Alanko, Jerkeman, A., Aleman, S., Kamal, H., Alghamdi, A., Alghamdi, M., Alghamdi, S., Al-Hamoudi, W., Ali, E., Aljumah, A., Altraif, I., Amarsanaa, J., Asselah, T., Baatarkhuu, O., Babameto, A., Ben-Ari, Z., Berg, T., Biondi, M., Braga, W., Brandão-Mello, C., Brown, R., Brunetto, M., Cabezas, J., Cardoso, M., Martins, A., Chan, H.L.Y., Cheinquer, H., Chen, C.-J., Yang, H.-I., Chen, P.-J., Chien, C.-H., Chuang, W.-L., Garza, L. Cisneros, Coco, B., Coffin, C., Coppola, N., Cornberg, M., Craxi, A., Crespo, J., Cuko, L., De Ledinghen, V., Duberg, A.-S., Etzion, O., Ferraz, M.L., Ferreira, P., Forns, X., Foster, G., Fung, J., Gaeta, G., García-Samaniego, J., Genov, J., Gheorghe, L., Gholam, P., Gish, R., Glenn, J., Hamid, S., Hercun, J., Hsu, Y.-C., Hu, C.-C., Huang, J.-F., Idilman, R., Jafri, W., Janjua, N., Jelev, D., Jia, J., Kåberg, M., Kaita, K., Kao, J.-H., Khan, A., Kim, D.Y., Kondili, L., Lagging, M., Lampertico, P., Lázaro, P., Lazarus, J.V., Lee, M.-H., Lim, Y.-S., Lobato, C., Macedo, G., Marinho, R., Marotta, P., Mendes-Correa, M.C., Méndez-Sánchez, N., Navas, M.-C., Ning, Q., Örmeci, N., Orrego, M., Osiowy, C., Pan, C., Pessoa, M., Piracha, Z., Pop, C., Qureshi, H., Raimondo, G., Ramji, A., Ribeiro, S., Ríos-Hincapié, C., Rodríguez, M., Rosenberg, W., Roulot, D., Ryder, S., Saeed, U., Safadi, R., Shouval, D., Sanai, F., Sanchez-Avila, J.F., Santantonio, T., Sarrazin, C., Seto, W.-K., Simonova, M., Tanaka, J., Tergast, T., Tsendsuren, O., Valente, C., Villalobos-Salcedo, J.M., Waheed, Y., Wong, G., Wong, V., Yip, T., Wu, J.-C., Yu, M.-L., Yuen, M.-F., Yurdaydin, C., and Zuckerman, E.

Published
2024
Full Text
View/download PDF

6. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study

Author

Cornberg, Markus, Ahumada, Adriana, Aghemo, Alessio, Andreoni, Massimo, Bhagat, Abhi, Butrymowicz, Isabel, Carmiel, Michal, Chodick, Gabriel, Conway, Brian, Song, Yanna, Gasbarrini, Antonio, Hüppe, Dietrich, Plaza, Francisco Jorquera, Lampertico, Pietro, Alonso, Maria Luisa Manzano, Myles, Lindsay, Persico, Marcello, Ramji, Alnoor, Sarrazin, Christoph, Villa, Erica, Weil, Clara, and Otano, Juan Isidro Uriz

Published
2022
Full Text
View/download PDF

8. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

Author

Kondili, L, Brancaccio, G, Tosti, M, Coco, B, Quaranta, M, Messina, V, Ciancio, A, Morisco, F, Cossiga, V, Claar, E, Rosato, V, Ciarallo, M, Cacciola, I, Ponziani, F, Cerrito, L, Coppola, R, Longobardi, F, Biliotti, E, Rianda, A, Barbaro, F, Coppola, N, Stanzione, M, Barchiesi, F, Fagiuoli, S, Vigano, M, Massari, M, Russo, F, Ferrarese, A, Laccabue, D, Di Marco, V, Blanc, P, Marrone, A, Morsica, G, Federico, A, Ieluzzi, D, Rocco, A, Foschi, F, Soria, A, Maida, I, Chessa, L, Milella, M, Rosselli Del Turco, E, Madonia, S, Chemello, L, Gentile, I, Toniutto, P, Bassetti, M, Surace, L, Baiocchi, L, Pellicelli, A, De Santis, A, Puoti, M, Degasperi, E, Niro, G, Zignego, A, Craxi, A, Raimondo, G, Santantonio, T, Brunetto, M, Gaeta, G, Aghemo, A, Baiguera, C, Battezzati, P, Battistella, S, Bavetta, M, Bertoni, C, Boni, C, Brambilla, P, Bray, A, Briano, F, Carmenini, E, Castelli, F, Cavalletto, L, Cerini, F, Chidichimo, L, Colella, E, Cologni, G, Como, S, Corsini, R, Costa, C, Cotugno, R, Cretella, S, De Angelis, F, De Leo, P, Perri, G, Falbo, E, Ferrigno, L, Fornasiere, E, Francisci, D, Gatti, P, Lampertico, P, Lenci, I, Licata, A, Marzano, A, Mastroianni, A, Mazzaro, C, Monti, M, Nardone, G, Nicolini, L, Passigato, N, Pasticci, M, Pierotti, P, Pinchera, B, Pollicino, T, Porcu, C, Quartini, G, Rancatore, G, Romeo, M, Rumi, M, Saracino, A, Schioppa, O, Serio, I, Soffredini, R, Tata, X, Tizzani, M, Tonnini, M, Torti, C, Valenti, D, Zaltron, S, Zoncada, A, Kondili L. A., Brancaccio G., Tosti M. E., Coco B., Quaranta M. G., Messina V., Ciancio A., Morisco F., Cossiga V., Claar E., Rosato V., Ciarallo M., Cacciola I., Ponziani F. R., Cerrito L., Coppola R., Longobardi F., Biliotti E., Rianda A., Barbaro F., Coppola N., Stanzione M., Barchiesi F., Fagiuoli S., Vigano M., Massari M., Russo F. P., Ferrarese A., Laccabue D., Di Marco V., Blanc P., Marrone A., Morsica G., Federico A., Ieluzzi D., Rocco A., Foschi F. G., Soria A., Maida I., Chessa L., Milella M., Rosselli Del Turco E., Madonia S., Chemello L., Gentile I., Toniutto P., Bassetti M., Surace L., Baiocchi L., Pellicelli A., De Santis A., Puoti M., Degasperi E., Niro G. A., Zignego A. L., Craxi A., Raimondo G., Santantonio T. A., Brunetto M. R., Gaeta G. B., Aghemo A., Baiguera C., Battezzati P. M., Battistella S., Bavetta M. G., Bertoni C., Boni C., Brambilla P., Bray A., Briano F., Carmenini E., Castelli F., Cavalletto L., Cerini F., Chidichimo L., Colella E., Cologni G., Como S., Corsini R., Costa C., Cotugno R., Cretella S., De Angelis F., De Leo P., Perri G. D., Falbo E., Ferrigno L., Fornasiere E., Francisci D., Gatti P., Lampertico P., Lenci I., Licata A., Marzano A., Mastroianni A., Mazzaro C., Monti M., Nardone G., Nicolini L. A., Passigato N., Pasticci M. B., Pierotti P., Pinchera B., Pollicino T., Porcu C., Quartini G., Rancatore G., Romeo M., Rumi M. G., Saracino A., Schioppa O., Serio I., Soffredini R., Tata X., Tizzani M., Tonnini M., Torti C., Valenti D., Zaltron S., Zoncada A., Kondili, L, Brancaccio, G, Tosti, M, Coco, B, Quaranta, M, Messina, V, Ciancio, A, Morisco, F, Cossiga, V, Claar, E, Rosato, V, Ciarallo, M, Cacciola, I, Ponziani, F, Cerrito, L, Coppola, R, Longobardi, F, Biliotti, E, Rianda, A, Barbaro, F, Coppola, N, Stanzione, M, Barchiesi, F, Fagiuoli, S, Vigano, M, Massari, M, Russo, F, Ferrarese, A, Laccabue, D, Di Marco, V, Blanc, P, Marrone, A, Morsica, G, Federico, A, Ieluzzi, D, Rocco, A, Foschi, F, Soria, A, Maida, I, Chessa, L, Milella, M, Rosselli Del Turco, E, Madonia, S, Chemello, L, Gentile, I, Toniutto, P, Bassetti, M, Surace, L, Baiocchi, L, Pellicelli, A, De Santis, A, Puoti, M, Degasperi, E, Niro, G, Zignego, A, Craxi, A, Raimondo, G, Santantonio, T, Brunetto, M, Gaeta, G, Aghemo, A, Baiguera, C, Battezzati, P, Battistella, S, Bavetta, M, Bertoni, C, Boni, C, Brambilla, P, Bray, A, Briano, F, Carmenini, E, Castelli, F, Cavalletto, L, Cerini, F, Chidichimo, L, Colella, E, Cologni, G, Como, S, Corsini, R, Costa, C, Cotugno, R, Cretella, S, De Angelis, F, De Leo, P, Perri, G, Falbo, E, Ferrigno, L, Fornasiere, E, Francisci, D, Gatti, P, Lampertico, P, Lenci, I, Licata, A, Marzano, A, Mastroianni, A, Mazzaro, C, Monti, M, Nardone, G, Nicolini, L, Passigato, N, Pasticci, M, Pierotti, P, Pinchera, B, Pollicino, T, Porcu, C, Quartini, G, Rancatore, G, Romeo, M, Rumi, M, Saracino, A, Schioppa, O, Serio, I, Soffredini, R, Tata, X, Tizzani, M, Tonnini, M, Torti, C, Valenti, D, Zaltron, S, Zoncada, A, Kondili L. A., Brancaccio G., Tosti M. E., Coco B., Quaranta M. G., Messina V., Ciancio A., Morisco F., Cossiga V., Claar E., Rosato V., Ciarallo M., Cacciola I., Ponziani F. R., Cerrito L., Coppola R., Longobardi F., Biliotti E., Rianda A., Barbaro F., Coppola N., Stanzione M., Barchiesi F., Fagiuoli S., Vigano M., Massari M., Russo F. P., Ferrarese A., Laccabue D., Di Marco V., Blanc P., Marrone A., Morsica G., Federico A., Ieluzzi D., Rocco A., Foschi F. G., Soria A., Maida I., Chessa L., Milella M., Rosselli Del Turco E., Madonia S., Chemello L., Gentile I., Toniutto P., Bassetti M., Surace L., Baiocchi L., Pellicelli A., De Santis A., Puoti M., Degasperi E., Niro G. A., Zignego A. L., Craxi A., Raimondo G., Santantonio T. A., Brunetto M. R., Gaeta G. B., Aghemo A., Baiguera C., Battezzati P. M., Battistella S., Bavetta M. G., Bertoni C., Boni C., Brambilla P., Bray A., Briano F., Carmenini E., Castelli F., Cavalletto L., Cerini F., Chidichimo L., Colella E., Cologni G., Como S., Corsini R., Costa C., Cotugno R., Cretella S., De Angelis F., De Leo P., Perri G. D., Falbo E., Ferrigno L., Fornasiere E., Francisci D., Gatti P., Lampertico P., Lenci I., Licata A., Marzano A., Mastroianni A., Mazzaro C., Monti M., Nardone G., Nicolini L. A., Passigato N., Pasticci M. B., Pierotti P., Pinchera B., Pollicino T., Porcu C., Quartini G., Rancatore G., Romeo M., Rumi M. G., Saracino A., Schioppa O., Serio I., Soffredini R., Tata X., Tizzani M., Tonnini M., Torti C., Valenti D., Zaltron S., and Zoncada A.

Abstract

Background and Aims: We aimed to characterize the epidemiologic and comorbidities profiles of patients with chronic Hepatitis D (CHD) followed in clinical practice in Italy and explored their interferon (IFN) eligibility. Methods: This was a cross-sectional study of the PITER cohort consisting of consecutive HBsAg-positive patients from 59 centers over the period 2019-2023. Multivariable analysis was performed by logistic regression model. Results: Of 5492 HBsAg-positive enrolled patients, 4152 (75.6%) were screened for HDV, 422 (10.2%) were anti-HDV positive. Compared with HBsAg mono-infected, anti-HDV positive patients were more often younger, non-Italians, with a history of drug use, had elevated alanine transaminase (ALT), cirrhosis, or hepatocellular carcinoma (HCC). Compared with Italians, anti-HDV positive non-Italians were younger (42.2% age ≤ 40 years vs. 2.1%; P < 0.001), more often females (males 43.0% vs. 68.6%; P < 0.001) with less frequent cirrhosis and HCC. HDV-RNA was detected in 63.2% of anti-HDV-positive patients, who were more likely to have elevated ALT, cirrhosis, and HCC. Extrahepatic comorbidities were present in 47.4% of anti-HDV positive patients and could affect the eligibility of IFN-containing therapies in at least 53.0% of patients in care. Conclusions: CHD affects young, foreign-born patients and older Italians, of whom two-thirds had cirrhosis or HCC. Comorbidities were frequent in both Italians and non-Italians and impacted eligibility for IFN.

Published
2024

9. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Author

Burgio V, Iavarone M, Di Costanzo GG, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Celsa C, Foschi FG, Silletta M, Amoruso DC, Rimini M, Bruccoleri M, Tortora R, Campani C, Soldà C, Viola MG, Forgione A, Conti F, Salani F, Catanese S, Giacchetto CM, Fulgenzi C, Coppola C, Lampertico P, Pellino A, Rancatore G, Cabibbo G, Ratti F, Pedica F, Della Corte A, Colombo M, De Cobelli F, Aldrighetti L, Cascinu S, and Casadei-Gardini A

Subjects
hepatocarcinoma, sorafenib, lenvatinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14 Margherita Rimini,15 Mariangela Bruccoleri,2 Raffaella Tortora,3 Claudia Campani,4 Caterina Soldà,6 Massimo Giuseppe Viola,16 Antonella Forgione,8 Fabio Conti,12 Francesca Salani,9,10 Silvia Catanese,9,10 Carmelo Marco Giacchetto,17 Claudia Fulgenzi,13 Carmine Coppola,14 Pietro Lampertico,18 Antonio Pellino,6,19 Gabriele Rancatore,17 Giuseppe Cabibbo,17 Francesca Ratti,20 Federica Pedica,21 Angelo Della Corte,22 Massimo Colombo,18 Francesco De Cobelli,23 Luca Aldrighetti,20 Stefano Cascinu,1,23 Andrea Casadei-Gardini1,23 1Department of Medical Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 2Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; 3Department of Hepatology, Naples, 80131, Italy; 4Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Firenze, Italy; 5Early Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; 6Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 7Department of Oncology and Palliative Care, Cardinale Hospital, Naples, Italy; 8Division of Internal Medicine, Hepatobiliary and Immunoallergic Disease, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 9Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; 10Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; 11Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.), University of Palermo, Palermo, 90127, Italy; 12Internal Medicine, Infermi Hospital, Faenza (AUSL ROMAGNA), Ravenna, Italy; 13Department of Oncology, Campus Bio Medico, Roma, Italy; 14Hepatology Unit, Internal Medicine, Area Stabiese Hospital, Naples, Italy; 15Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, Modena, 4121, Italy; 16Department of General Surgery and Emergency Surgery, Cardinale Hospital, Tricase, Italy; 17Section of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, 90127, Italy; 18Liver Center, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 19Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; 20Hepatobiliary Surgery Division, Liver Center, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 21Department of Experimental Oncology, Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 22Department of Radiology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 23School of Medicine, Vita-Salute San Raffaele University, Milan, 20132, ItalyCorrespondence: Andrea Casadei-GardiniDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Via Olgettina n. 60, Milan, ItalyEmail casadeigardini@gmail.comBackground: Lenvatinib has been approved in Italy since October 2019 as a first-line therapy for advanced hepatocellular carcinoma (HCC) and to date data on effectiveness and safety of lenvatinib are not available in our region. To fill this gap, we performed a multicentric analysis of the real-world treatment outcomes with the propensity score matching in a cohort of Italian patients with unresectable HCC who were treated with either sorafenib or lenvatinib.Aims and Methods: To evaluate the effectiveness of sorafenib and lenvatinib as primary treatment of advanced HCC in clinical practice we performed a multicentric analysis of the treatment outcomes of 288 such patients recruited in 11 centers in Italy. A propensity score was used to mitigate confounding due to referral biases in the assessment of mortality and progression-free survival.Results: Over a follow-up period of 11 months the Cox regression model showed 48% reduction of death risk for patients treated with lenvatinib (95% CI: 0.34– 0.81; p = 0.0034), compared with those treated with sorafenib. The median PFS was 9.0 and 4.9 months for lenvatinib and sorafenib arm, respectively. Patients treated with lenvatinib showed a higher percentage of response rate (29.4% vs 2.8%; p < 0.00001) compared with patients treated with sorafenib. Sorafenib was shown to be correlated with more HFSR, diarrhea and fatigue, while lenvatinib with more hypertension and fatigue.Conclusion: Our study highlighted for the first time the efficacy and safety of lenvatinib in an Italian cohort of patients.Keywords: hepatocarcinoma, sorafenib, lenvatinib

Published
2021

10. Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir

Author

Aghemo, Alessio, Horsmans, Yves, Bourgeois, Stefan, Bondin, Mark, Gschwantler, Michael, Hofer, Harald, Semmo, Nasser, Negro, Francesco, Zhang, Zhenzhen, Marcinak, John, Veitsman, Ella, Hazzan, Rawi, Mimidis, Konstantinos, Goulis, Ioannis, Marques, Nuno, Flisiak, Robert, Mazur, Wlodzimierz, Roncero, Carlos, Marra, Fiona, Pageaux, Georges Philippe, Asselah, Tarik, and Lampertico, Pietro

Published
2021
Full Text
View/download PDF

14. OC.05.2: FIRST AND FURTHER LIVER DECOMPENSATION IN PATIENTS WITH METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE: WHAT CLINICAL IMPACT?

Author

Pennisi, G., primary, Viganò, M., additional, Fracanzani, A.L., additional, Miele, L., additional, Bugianesi, E., additional, D'Ambrosio, R., additional, Ravaioli, F., additional, Schepis, F., additional, Marra, F., additional, Aghemo, A.M.G., additional, Svegliati Baroni, G., additional, Masarone, M., additional, Valenti, L., additional, Armandi, A., additional, Ciccioli, C., additional, Cerini, F., additional, Colecchia, A., additional, Gasbarrini, A., additional, Infantino, G., additional, Liguori, A., additional, Pelusi, S., additional, Saltini, D., additional, Lampertico, P., additional, Persico, M., additional, Pugliese, N., additional, Tulone, A., additional, Di Marco, V., additional, Cammà, C., additional, and Petta, S., additional

Published
2024
Full Text
View/download PDF

15. OC.05.7: CHOLESTASIS IMPACTS ON PERFORMANCE OF NON INVASIVE TESTS FOR RULING OUT HIGH-RISK ESOPHAGEALVARICES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED ADVANCED CHRONIC LIVER DISEASE

Author

Calvaruso, V., primary, Celsa, C., additional, Cristoferi, L., additional, Scaravaglio, M., additional, Capodicasa, L., additional, Di Maria, G., additional, Cadamuro, L., additional, Gerussi, A., additional, Malinverno, F., additional, Lampertico, P., additional, Cazzagon, N., additional, Marzioni, M., additional, Vespasiani Gentilucci, U., additional, Andreone, P., additional, Lleo, A., additional, Rigamonti, C., additional, Viganò, M., additional, Giannini, E.G., additional, Russello, M., additional, Vanni, E., additional, Cerini, F., additional, Missale, G., additional, Brunetto, M.R., additional, Niro, G., additional, Vettori, G., additional, Castellaneta, A., additional, Cardinale, V., additional, Alvaro, D., additional, Mega, A., additional, Pace Palitti, V., additional, Bellanti, F., additional, Di Marco, V., additional, Invernizzi, P., additional, Cammà, C., additional, and Carbone, M., additional

Published
2024
Full Text
View/download PDF

17. Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir

Author

Aghemo, Alessio, Horsmans, Yves, Bourgeois, Stefan, Bondin, Mark, Gschwantler, Michael, Hofer, Harald, Semmo, Nasser, Negro, Francesco, Zhang, Zhenzhen, Marcinak, John, Veitsman, Ella, Hazzan, Rawi, Mimidis, Konstantinos, Goulis, Ioannis, Marques, Nuno, Flisiak, Robert, Mazur, Wlodzimierz, Roncero, Carlos, Marra, Fiona, Pageaux, Georges Philippe, Asselah, Tarik, and Lampertico, Pietro

Published
2021
Full Text
View/download PDF

19. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

Author

Kondili, L, Quaranta, M, Cavalletto, L, Calvaruso, V, Ferrigno, L, D'Ambrosio, R, Simonelli, I, Brancaccio, G, Raimondo, G, Brunetto, M, Zignego, A, Coppola, C, Iannone, A, Biliotti, E, Verucchi, G, Massari, M, Licata, A, Barbaro, F, Persico, M, Russo, F, Morisco, F, Pompili, M, Vigano, M, Puoti, M, Santantonio, T, Villa, E, Craxi, A, Chemello, L, Panetta, V, Gaeta, G, Filomia, R, Coco, B, Monti, M, Amoruso, D, Madonia, S, Ieluzzi, D, Taliani, G, Badia, L, Migliorino, G, Giorgini, A, Masarone, M, Blanc, P, Cossiga, V, De Siena, M, Tata, X, Rumi, M, Chessa, L, Lampertico, P, Ferrari, C, Gentile, I, Parruti, G, Baiocchi, L, Ciancio, A, Invernizzi, P, Federico, A, Torti, C, Morsica, G, Andreone, P, Aghemo, A, Popoli, P, Vella, S, Kondili L. A., Quaranta M. G., Cavalletto L., Calvaruso V., Ferrigno L., D'Ambrosio R., Simonelli I., Brancaccio G., Raimondo G., Brunetto M. R., Zignego A. L., Coppola C., Iannone A., Biliotti E., Verucchi G., Massari M., Licata A., Barbaro F., Persico M., Russo F. P., Morisco F., Pompili M., Vigano M., Puoti M., Santantonio T., Villa E., Craxi A., Chemello L., Panetta V., Gaeta G. B., Filomia R., Coco B., Monti M., Amoruso D. C., Madonia S., Ieluzzi D., Taliani G., Badia L., Migliorino G. M., Giorgini A., Masarone M., Blanc P., Cossiga V., De Siena M., Tata X., Rumi M. G., Chessa L., Lampertico P., Ferrari C., Gentile I., Parruti G., Baiocchi L., Ciancio A., Invernizzi P., Federico A., Torti C., Morsica G., Andreone P., Aghemo A., Popoli P., Vella S., Kondili, L, Quaranta, M, Cavalletto, L, Calvaruso, V, Ferrigno, L, D'Ambrosio, R, Simonelli, I, Brancaccio, G, Raimondo, G, Brunetto, M, Zignego, A, Coppola, C, Iannone, A, Biliotti, E, Verucchi, G, Massari, M, Licata, A, Barbaro, F, Persico, M, Russo, F, Morisco, F, Pompili, M, Vigano, M, Puoti, M, Santantonio, T, Villa, E, Craxi, A, Chemello, L, Panetta, V, Gaeta, G, Filomia, R, Coco, B, Monti, M, Amoruso, D, Madonia, S, Ieluzzi, D, Taliani, G, Badia, L, Migliorino, G, Giorgini, A, Masarone, M, Blanc, P, Cossiga, V, De Siena, M, Tata, X, Rumi, M, Chessa, L, Lampertico, P, Ferrari, C, Gentile, I, Parruti, G, Baiocchi, L, Ciancio, A, Invernizzi, P, Federico, A, Torti, C, Morsica, G, Andreone, P, Aghemo, A, Popoli, P, Vella, S, Kondili L. A., Quaranta M. G., Cavalletto L., Calvaruso V., Ferrigno L., D'Ambrosio R., Simonelli I., Brancaccio G., Raimondo G., Brunetto M. R., Zignego A. L., Coppola C., Iannone A., Biliotti E., Verucchi G., Massari M., Licata A., Barbaro F., Persico M., Russo F. P., Morisco F., Pompili M., Vigano M., Puoti M., Santantonio T., Villa E., Craxi A., Chemello L., Panetta V., Gaeta G. B., Filomia R., Coco B., Monti M., Amoruso D. C., Madonia S., Ieluzzi D., Taliani G., Badia L., Migliorino G. M., Giorgini A., Masarone M., Blanc P., Cossiga V., De Siena M., Tata X., Rumi M. G., Chessa L., Lampertico P., Ferrari C., Gentile I., Parruti G., Baiocchi L., Ciancio A., Invernizzi P., Federico A., Torti C., Morsica G., Andreone P., Aghemo A., Popoli P., and Vella S.

Abstract

Background and aims: Severe liver disease markers assessed before HCV eradication are acknowledged to usually improve after the SVR. We prospectively evaluated, in the PITER cohort, the long-term HCC risk profile based on predictors monitored after HCV eradication by direct-acting antivirals in patients with cirrhosis. Methods: HCC occurrence was evaluated by Kaplan-Meier analysis. Cox regression analysis identified the post-treatment variables associated with de-novo HCC; their predictive power was presented in a nomogram. Results: After the end of therapy (median follow-up:28.47 months), among 2064 SVR patients, 119 (5.8%) developed de-novo HCC. The HCC incidence was 1.90%, 4.21%, 6.47% at 12-, 24- and 36-months from end-of-therapy, respectively (incidence rate 2.45/100 person-years). Age, genotype 3, diabetes, platelets (PLT)≤120,000/µl and albumin ≤3.5g/dl levels were identified as pre-treatment HCC independent predictors. Adjusting for age, the post-treatment PLT≤120,000/µl (AdjHR 1.92; 95%CI:1.06-3.45) and albumin≤3.5g/dl (AdjHR 4.38; 95%CI 2.48-7.75) values were independently associated with HCC occurrence. Two different risk profiles were identified by combining long-term post-therapy evaluation of PLT ≤ vs. >120,000/µl and albumin ≤ vs. >3.5g/dl showing a significant different HCC incidence rate of 1.35 vs. 3.77/100 p-y, respectively. Conclusions: The nomogram score based on age, PLT and albumin levels after SVR showed an accurate prediction capability and may support the customizing management for early HCC detection.

Published
2023

20. A territory-wide opportunistic, hospital-based HCV screening in the general population from northern Italy: The 1969–1989 birth-cohort

Author

D'Ambrosio, R, Piccinelli, S, Beccalli, B, Spinetti, A, Puoti, M, Fagiuoli, S, Magni, C, Vavassori, A, Sacchi, P, Castaldi, S, Bombardieri, G, Farina, C, Buoro, S, Amorosi, A, Corradin, M, Cereda, D, Lampertico, P, D'Ambrosio R., Piccinelli S., Beccalli B., Spinetti A., Puoti M., Fagiuoli S., Magni C. F., Vavassori A., Sacchi P., Castaldi S., Bombardieri G., Farina C., Buoro S., Amorosi A., Corradin M., Cereda D., Lampertico P., D'Ambrosio, R, Piccinelli, S, Beccalli, B, Spinetti, A, Puoti, M, Fagiuoli, S, Magni, C, Vavassori, A, Sacchi, P, Castaldi, S, Bombardieri, G, Farina, C, Buoro, S, Amorosi, A, Corradin, M, Cereda, D, Lampertico, P, D'Ambrosio R., Piccinelli S., Beccalli B., Spinetti A., Puoti M., Fagiuoli S., Magni C. F., Vavassori A., Sacchi P., Castaldi S., Bombardieri G., Farina C., Buoro S., Amorosi A., Corradin M., Cereda D., and Lampertico P.

Abstract

Background and Aim: The World Health Organization (WHO) goal of Hepatitis C Virus (HCV) elimination by 2030 rose awareness about the need of screening plans, worldwide. In Italy, graduated screening starting from people born in 1969–1989 might be the most-effective strategy. We performed an opportunistic HCV screening study in the general population attending health facilities in Lombardy region, Northern Italy. Methods: This is a prospective, multicenter, territory-wide, opportunistic study supported by the Regional Government of Lombardy, Italy. Between June 2022 and December 2022, all subjects born in 1969–1989, hospitalized or accessing blood collection centres were offered anti-HCV and HCV–RNA tests. Patients with known anti-HCV positivity and/or previous anti-HCV treatment were excluded. Demographic features were uploaded into a regional web-based platform. Results: In total, 120 193 individuals were screened in 75 centres. Mean age was 44 (±6) years, 65.2% were females, 83.7% were tested at blood collection centres. Anti-HCV tested positive in 604 (0.50%) subjects: mean age 47 (±5), 51.1% females. HCV seroprevalence was higher in males (p < 0.00001), elderly (p < 0.00001) and in- vs. outpatients (p = 0.0009). HCV–RNA was detectable in 125 out of 441 (28.3%) anti-HCV positive subjects. Actively infected patients were 46 (±6) years old, mainly males (56.8%). The overall prevalence of active HCV infection was 0.10%, higher in elderly (p = 0.0003) and in in-patients (p = 0.0007). Among 93 HCV–RNA positive patients, the median age was 48 years, 58% males, 62% Italian born, median HCV–RNA levels were 6,1 log IU/mL, liver stiffness measurement (LSM) values 5.5 (3.1–29.9) kPa and ALT levels 48 U/L. Conclusions: The prevalence of active HCV infection in the 1969–1989 population attending health facilities in Lombardy was low. Most viremic patients were Italian-born, with mild liver disease but high-HCV–RNA levels. Due to the higher prevalence in the elderly, the

Published
2023

21. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

Author

Brancaccio, G, Coco, B, Nardi, A, Quaranta, M, Tosti, M, Ferrigno, L, Cacciola, I, Messina, V, Chessa, L, Morisco, F, Milella, M, Barbaro, F, Ciancio, A, Russo, F, Coppola, N, Blanc, P, Claar, E, Verucchi, G, Puoti, M, Zignego, A, Chemello, L, Madonia, S, Fagiuoli, S, Marzano, A, Ferrari, C, Lampertico, P, Di Marco, V, Craxì, A, Santantonio, T, Raimondo, G, Brunetto, M, Gaeta, G, Kondili, L, Pasulo, L, Coppola, C, Pisano, F, Romano, M, Porcu, C, Bottalico, I, Cossiga, V, Tata, X, Sagnelli, C, Pierotti, P, Degasperi, E, Rosato, V, Badia, L, Ieluzzi, D, Monti, M, Bavetta, M, Cavalletto, L, Toniutto, P, Fornasiere, E, Colecchia, A, Ferrarese, A, Nardone, G, Rocco, A, Viganò, M, Foschi, F, Conti, F, Morsica, G, Salpietro, S, Torti, C, Costa, C, Federico, A, Dallio, M, Giorgini, A, Anselmo, M, De Leo, P, Zaltron, S, Cambianica, A, Piscaglia, F, Serio, I, Schivazappa, S, Mastroianni, A, Chidichimo, L, Massari, M, Mazzaro, C, Marrone, A, D'Amore, F, D'Offizi, G, Licata, A, Niro, G, Pollicino, T, Aghemo, A, Brancaccio G., Coco B., Nardi A., Quaranta M. G., Tosti M. E., Ferrigno L., Cacciola I., Messina V., Chessa L., Morisco F., Milella M., Barbaro F., Ciancio A., Russo F. P., Coppola N., Blanc P., Claar E., Verucchi G., Puoti M., Zignego A. L., Chemello L., Madonia S., Fagiuoli S., Marzano A., Ferrari C., Lampertico P., Di Marco V., Craxì A., Santantonio T. A., Raimondo G., Brunetto M. R., Gaeta G. B., Kondili L. A., Pasulo L., Coppola C., Pisano F., Romano M., Porcu C., Bottalico I. F., Cossiga V., Tata X., Sagnelli C., Pierotti P., Degasperi E., Rosato V., Badia L., Ieluzzi D., Monti M., Bavetta M. G., Cavalletto L., Toniutto P., Fornasiere E., Colecchia A., Ferrarese A., Nardone G., Rocco A., Viganò M., Foschi F. G., Conti F., Morsica G., Salpietro S., Torti C., Costa C., Federico A., Dallio M., Giorgini A., Anselmo M., De Leo P., Zaltron S., Cambianica A., Piscaglia F., Serio I., Schivazappa S., Mastroianni A., Chidichimo L., Massari M., Mazzaro C., Marrone A., D'Amore F. M., D'Offizi G., Licata A., Niro G. A., Pollicino T., Aghemo A., Brancaccio, G, Coco, B, Nardi, A, Quaranta, M, Tosti, M, Ferrigno, L, Cacciola, I, Messina, V, Chessa, L, Morisco, F, Milella, M, Barbaro, F, Ciancio, A, Russo, F, Coppola, N, Blanc, P, Claar, E, Verucchi, G, Puoti, M, Zignego, A, Chemello, L, Madonia, S, Fagiuoli, S, Marzano, A, Ferrari, C, Lampertico, P, Di Marco, V, Craxì, A, Santantonio, T, Raimondo, G, Brunetto, M, Gaeta, G, Kondili, L, Pasulo, L, Coppola, C, Pisano, F, Romano, M, Porcu, C, Bottalico, I, Cossiga, V, Tata, X, Sagnelli, C, Pierotti, P, Degasperi, E, Rosato, V, Badia, L, Ieluzzi, D, Monti, M, Bavetta, M, Cavalletto, L, Toniutto, P, Fornasiere, E, Colecchia, A, Ferrarese, A, Nardone, G, Rocco, A, Viganò, M, Foschi, F, Conti, F, Morsica, G, Salpietro, S, Torti, C, Costa, C, Federico, A, Dallio, M, Giorgini, A, Anselmo, M, De Leo, P, Zaltron, S, Cambianica, A, Piscaglia, F, Serio, I, Schivazappa, S, Mastroianni, A, Chidichimo, L, Massari, M, Mazzaro, C, Marrone, A, D'Amore, F, D'Offizi, G, Licata, A, Niro, G, Pollicino, T, Aghemo, A, Brancaccio G., Coco B., Nardi A., Quaranta M. G., Tosti M. E., Ferrigno L., Cacciola I., Messina V., Chessa L., Morisco F., Milella M., Barbaro F., Ciancio A., Russo F. P., Coppola N., Blanc P., Claar E., Verucchi G., Puoti M., Zignego A. L., Chemello L., Madonia S., Fagiuoli S., Marzano A., Ferrari C., Lampertico P., Di Marco V., Craxì A., Santantonio T. A., Raimondo G., Brunetto M. R., Gaeta G. B., Kondili L. A., Pasulo L., Coppola C., Pisano F., Romano M., Porcu C., Bottalico I. F., Cossiga V., Tata X., Sagnelli C., Pierotti P., Degasperi E., Rosato V., Badia L., Ieluzzi D., Monti M., Bavetta M. G., Cavalletto L., Toniutto P., Fornasiere E., Colecchia A., Ferrarese A., Nardone G., Rocco A., Viganò M., Foschi F. G., Conti F., Morsica G., Salpietro S., Torti C., Costa C., Federico A., Dallio M., Giorgini A., Anselmo M., De Leo P., Zaltron S., Cambianica A., Piscaglia F., Serio I., Schivazappa S., Mastroianni A., Chidichimo L., Massari M., Mazzaro C., Marrone A., D'Amore F. M., D'Offizi G., Licata A., Niro G. A., Pollicino T., and Aghemo A.

Abstract

Objectives: The study measures trends in the profile of patients with chronic hepatitis B virus linked to care in Italy. Methods: A cross-sectional, multicenter, observational cohort (PITER cohort) of consecutive patients with hepatitis B surface antigen (HBsAg) over the period 2019-2021 from 46 centers was evaluated. The reference was the MASTER cohort collected over the years 2012-2015. Standard statistical methods were used. Results: The PITER cohort enrolled 4583 patients, of whom 21.8% were non-Italian natives. Compared with those in MASTER, the patients were older and more often female. The prevalence of hepatitis B e antigen (HBeAg) declined (7.2% vs 12.3; P <0.0001) and that of anti-hepatitis D virus (HDV) remained stable (9.3% vs 8.3%). In both cohorts, about 25% of the patients had cirrhosis, and those in the PITER cohort were older. HBeAg-positive was 5.0% vs 12.6% (P <0.0001) and anti-HDV positive 24.8% vs 17.5% (P <0.0017). In the logistic model, the variables associated with cirrhosis were anti-HDV-positive (odds ratio = 10.08; confidence interval 7.63-13.43), age, sex, and body mass index; the likelihood of cirrhosis was reduced by 40% in the PITER cohort. Among non-Italians, 12.3% were HBeAg-positive (vs 23.4% in the MASTER cohort; P <0.0001), and 12.3% were anti-HDV-positive (vs 11.1%). Overall, the adherence to the European Association for the Study of the Liver recommendations for antiviral treatment increased over time. Conclusion: Chronic hepatitis B virus infection appears to be in the process of becoming under control in Italy; however, HDV infection is still a health concern in patients with cirrhosis and in migrants.

Published
2023

22. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

Author

Razavi-Shearer, D., primary, Child, H., additional, Razavi-Shearer, K., additional, Voeller, A., additional, Razavi, H., additional, Buti, M., additional, Tacke, F., additional, Terrault, N., additional, Zeuzem, S., additional, Abbas, Z., additional, Aghemo, A., additional, Akarca, U.S., additional, Al Masri, N., additional, Alalwan, A., additional, Blomé, M Alanko, additional, Jerkeman, A., additional, Aleman, S., additional, Kamal, H., additional, Alghamdi, A., additional, Alghamdi, M., additional, Alghamdi, S., additional, Al-Hamoudi, W., additional, Ali, E., additional, Aljumah, A., additional, Altraif, I., additional, Amarsanaa, J., additional, Asselah, T., additional, Baatarkhuu, O., additional, Babameto, A., additional, Ben-Ari, Z., additional, Berg, T., additional, Biondi, M., additional, Braga, W., additional, Brandão-Mello, C., additional, Brown, R., additional, Brunetto, M., additional, Cabezas, J., additional, Cardoso, M., additional, Martins, A., additional, Chan, H.L.Y., additional, Cheinquer, H., additional, Chen, C.-J., additional, Yang, H.-I., additional, Chen, P.-J., additional, Chien, C.-H., additional, Chuang, W.-L., additional, Garza, L Cisneros, additional, Coco, B., additional, Coffin, C., additional, Coppola, N., additional, Cornberg, M., additional, Craxi, A., additional, Crespo, J., additional, Cuko, L., additional, De Ledinghen, V., additional, Duberg, A.-S., additional, Etzion, O., additional, Ferraz, M.L., additional, Ferreira, P., additional, Forns, X., additional, Foster, G., additional, Fung, J., additional, Gaeta, G., additional, García-Samaniego, J., additional, Genov, J., additional, Gheorghe, L., additional, Gholam, P., additional, Gish, R., additional, Glenn, J., additional, Hamid, S., additional, Hercun, J., additional, Hsu, Y.-C., additional, Hu, C.-C., additional, Huang, J.-F., additional, Idilman, R., additional, Jafri, W., additional, Janjua, N., additional, Jelev, D., additional, Jia, J., additional, Kåberg, M., additional, Kaita, K., additional, Kao, J.-H., additional, Khan, A., additional, Kim, D.Y., additional, Kondili, L., additional, Lagging, M., additional, Lampertico, P., additional, Lázaro, P., additional, Lazarus, J.V., additional, Lee, M.-H., additional, Lim, Y.-S., additional, Lobato, C., additional, Macedo, G., additional, Marinho, R., additional, Marotta, P., additional, Mendes-Correa, M.C., additional, Méndez-Sánchez, N., additional, Navas, M.-C., additional, Ning, Q., additional, Örmeci, N., additional, Orrego, M., additional, Osiowy, C., additional, Pan, C., additional, Pessoa, M., additional, Piracha, Z., additional, Pop, C., additional, Qureshi, H., additional, Raimondo, G., additional, Ramji, A., additional, Ribeiro, S., additional, Ríos-Hincapié, C., additional, Rodríguez, M., additional, Rosenberg, W., additional, Roulot, D., additional, Ryder, S., additional, Saeed, U., additional, Safadi, R., additional, Shouval, D., additional, Sanai, F., additional, Sanchez-Avila, J.F., additional, Santantonio, T., additional, Sarrazin, C., additional, Seto, W.-K., additional, Simonova, M., additional, Tanaka, J., additional, Tergast, T., additional, Tsendsuren, O., additional, Valente, C., additional, Villalobos-Salcedo, J.M., additional, Waheed, Y., additional, Wong, G., additional, Wong, V., additional, Yip, T., additional, Wu, J.-C., additional, Yu, M.-L., additional, Yuen, M.-F., additional, Yurdaydin, C., additional, and Zuckerman, E., additional

Published
2023
Full Text
View/download PDF

23. Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study

Author

Janssen, Harry L A, Lim, Young-Suk, Lampertico, Pietro, Heo, Jeong, Chen, Chi-Yi, Fournier, Claire, Tsang, Tak Yin Owen, Bae, Ho, Chen, Chien-Hung, Coffin, Carla S, Ahn, Sang Hoon, Trinh, Huy, Flaherty, John F, Abramov, Frida, Zhao, Yang, Liu, Yang, Lau, Audrey, German, Polina, Chuang, Wan-Long, Agarwal, Kosh, and Gane, Edward

Abstract

Phase 3 studies in patients with chronic hepatitis B have shown tenofovir alafenamide to have non-inferior efficacy to tenofovir disoproxil fumarate, with improved renal and bone safety. We conducted this study to evaluate the safety and efficacy of switching to tenofovir alafenamide in participants with chronic hepatitis B and renal or hepatic impairment.

Published
2024
Full Text
View/download PDF

24. Reproducibility and accuracy of a pocket-size ultrasound device in assessing liver steatosis.

Author

Costantino, Andrea, Piagnani, Alessandra, Caccia, Riccardo, Sorge, Andrea, Maggioni, Marco, Perbellini, Riccardo, Donato, Francesca, D'Ambrosio, Roberta, Sed, Nicole Piazza O, Valenti, Luca, Prati, Daniele, Vecchi, Maurizio, Lampertico, Pietro, and Fraquelli, Mirella

Abstract

This diagnostic prospective study compared the feasibility and diagnostic accuracy of Pocket-size Ultrasound Devices (PUDs) against standard ultrasound (US) in detecting liver steatosis using the controlled attenuation parameter (CAP) and liver biopsy as reference standards. Consecutive patients with chronic liver diseases were assessed for the presence of steatosis using PUD and US. A CAP cut-off value >275 dB/m was applied to establish ≥S1. A 26-patient subgroup underwent liver biopsy. PUD reproducibility was evaluated using Cohen's k statistic. Diagnostic accuracy of PUD and US was given as Sensibility (Sn), Specificity (Sp), Positive and Negative Predictive Values (PPV, NPV), positive and negative Likelihood Ratio (LR+, LR-). 81 consecutive patients (69% males) with multiple etiologies were enroled. PUD inter-observer agreement was good (k 0.77, 95%CI 0.62–0.93). PUD and US identified ≥S1 according to CAP values respectively with Sn 0.87, Sp 0.61, PPV 0.49, NPV 0.91, LR+ 2.04, LR- 0.07, AUROC 0.74 and Sn 0.96, Sp 0.54, PPV 0.47, NPV 0.97, LR+ 2.10, LR- 0.07, AUROC 0.75. PUD shows good reproducibility and diagnostic accuracy in ruling liver steatosis out, representing a useful point-of-care tool to avail of hepatologists interested in excluding NAFLD, but with basic US skills. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Hepatocellular Carcinoma in HIV-Infected Patients: Clinical Presentation and Outcomes

Author

Alimenti, E., primary, Monti, B., additional, Peracchi, F., additional, Fava, M., additional, Colella, E., additional, Columpsi, P., additional, Squillace, N., additional, Lapadula, G., additional, Lampertico, P., additional, Puoti, M., additional, Bonfanti, P., additional, Merli, M., additional, Soria, A., additional, De Silvestri, A., additional, and Iavarone, M., additional

Published
2023
Full Text
View/download PDF

28. Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (Journal of Hepatology (2021) 75(3) (572–581), (S0168827821003342), (10.1016/j.jhep.2021.04.055))

Author

Cordell H. J., Cordell, H, Fryett, J, Ueno, K, Darlay, R, Aiba, Y, Hitomi, Y, Kawashima, M, Nishida, N, Khor, S, Gervais, O, Kawai, Y, Nagasaki, M, Tokunaga, K, Tang, R, Shi, Y, Li, Z, Juran, B, Atkinson, E, Gerussi, A, Carbone, M, Asselta, R, Cheung, A, de Andrade, M, Baras, A, Horowitz, J, Ferreira, M, Sun, D, Jones, D, Flack, S, Spicer, A, Mulcahy, V, Byun, J, Han, Y, Sandford, R, Lazaridis, K, Amos, C, Hirschfield, G, Seldin, M, Invernizzi, P, Siminovitch, K, Ma, X, Nakamura, M, Mells, G, Mason, A, Vincent, C, Xie, G, Zhang, J, Affronti, A, Almasio, P, Alvaro, D, Andreone, P, Andriulli, A, Azzaroli, F, Battezzati, P, Benedetti, A, Bragazzi, M, Brunetto, M, Bruno, S, Calvaruso, V, Cardinale, V, Casella, G, Cazzagon, N, Ciaccio, A, Coco, B, Colli, A, Colloredo, G, Colombo, M, Colombo, S, Cristoferi, L, Cursaro, C, Croce, L, Crosignani, A, D'Amato, D, Donato, F, Elia, G, Fabris, L, Fagiuoli, S, Ferrari, C, Floreani, A, Galli, A, Giannini, E, Grattagliano, I, Lampertico, P, Lleo, A, Malinverno, F, Mancuso, C, Marra, F, Marzioni, M, Massironi, S, Mattalia, A, Miele, L, Milani, C, Morini, L, Morisco, F, Muratori, L, Muratori, P, Niro, G, O'Donnell, S, Picciotto, A, Portincasa, P, Rigamonti, C, Ronca, V, Rosina, F, Spinzi, G, Strazzabosco, M, Tiribelli, C, Toniutto, P, Valenti, L, Vinci, M, Zuin, M, Nakamura, H, Abiru, S, Nagaoka, S, Komori, A, Yatsuhashi, H, Ishibashi, H, Ito, M, Migita, K, Ohira, H, Katsushima, S, Naganuma, A, Sugi, K, Komatsu, T, Mannami, T, Matsushita, K, Yoshizawa, K, Makita, F, Nikami, T, Nishimura, H, Kouno, H, Ota, H, Komura, T, Nakamura, Y, Shimada, M, Hirashima, N, Komeda, T, Ario, K, Nakamuta, M, Yamashita, T, Furuta, K, Kikuchi, M, Naeshiro, N, Takahashi, H, Mano, Y, Tsunematsu, S, Yabuuchi, I, Shimada, Y, Yamauchi, K, Sugimoto, R, Sakai, H, Mita, E, Koda, M, Tsuruta, S, Kamitsukasa, H, Sato, T, Masaki, N, Kobata, T, Fukushima, N, Ohara, Y, Muro, T, Takesaki, E, Takaki, H, Yamamoto, T, Kato, M, Nagaoki, Y, Hayashi, S, Ishida, J, Watanabe, Y, Kobayashi, M, Koga, M, Saoshiro, T, Yagura, M, Hirata, K, Tanaka, A, Takikawa, H, Zeniya, M, Abe, M, Onji, M, Kaneko, S, Honda, M, Arai, K, Arinaga-Hino, T, Hashimoto, E, Taniai, M, Umemura, T, Joshita, S, Nakao, K, Ichikawa, T, Shibata, H, Yamagiwa, S, Seike, M, Honda, K, Sakisaka, S, Takeyama, Y, Harada, M, Senju, M, Yokosuka, O, Kanda, T, Ueno, Y, Kikuchi, K, Ebinuma, H, Himoto, T, Yasunami, M, Murata, K, Mizokami, M, Kawata, K, Shimoda, S, Miyake, Y, Takaki, A, Yamamoto, K, Hirano, K, Ichida, T, Ido, A, Tsubouchi, H, Chayama, K, Harada, K, Nakanuma, Y, Maehara, Y, Taketomi, A, Shirabe, K, Soejima, Y, Mori, A, Yagi, S, Uemoto, S, H, E, Tanaka, T, Yamashiki, N, Tamura, S, Sugawara, Y, Kokudo, N, Chalasani, N, Luketic, V, Odin, J, Chopra, K, Abecasis, G, Cantor, M, Coppola, G, Economides, A, Lotta, L, Overton, J, Reid, J, Shuldiner, A, Beechert, C, Forsythe, C, Fuller, E, Gu, Z, Lattari, M, Lopez, A, Schleicher, T, Padilla, M, Toledo, K, Widom, L, Wolf, S, Pradhan, M, Manoochehri, K, Ulloa, R, Bai, X, Balasubramanian, S, Barnard, L, Blumenfeld, A, Eom, G, Habegger, L, Hawes, A, Khalid, S, Maxwell, E, Salerno, W, Staples, J, Jones, M, Mitnaul, L, Sturgess, R, Healey, C, Yeoman, A, Gunasekera, A, Kooner, P, Kapur, K, Sathyanarayana, V, Kallis, Y, Subhani, J, Harvey, R, Mccorry, R, Rooney, P, Ramanaden, D, Evans, R, Mathialahan, T, Gasem, J, Shorrock, C, Bhalme, M, Southern, P, Tibble, J, Gorard, D, Jones, S, Srivastava, B, Foxton, M, Collins, C, Elphick, D, Karmo, M, Porras-Perez, F, Mendall, M, Yapp, T, Patel, M, Ede, R, Sayer, J, Jupp, J, Fisher, N, Carter, M, Koss, K, Shah, J, Piotrowicz, A, Scott, G, Grimley, C, Gooding, I, Williams, S, Tidbury, J, Lim, G, Cheent, K, Levi, S, Mansour, D, Beckley, M, Hollywood, C, Wong, T, Marley, R, Ramage, J, Gordon, H, Ridpath, J, Ngatchu, T, Bob Grover, V, Shidrawi, R, Abouda, G, Corless, L, Narain, M, Rees, I, Brown, A, Taylor-Robinson, S, Wilkins, J, Grellier, L, Banim, P, Das, D, Heneghan, M, Curtis, H, Matthews, H, Mohammed, F, Aldersley, M, Srirajaskanthan, R, Walker, G, Mcnair, A, Sharif, A, Sen, S, Bird, G, Prince, M, Prasad, G, Kitchen, P, Barnardo, A, Oza, C, Sivaramakrishnan, N, Gupta, P, Shah, A, Evans, C, Saha, S, Pollock, K, Bramley, P, Mukhopadhya, A, Barclay, S, Mcdonald, N, Bathgate, A, Palmer, K, Dillon, J, Rushbrook, S, Przemioslo, R, Mcdonald, C, Millar, A, Tai, C, Mitchell, S, Metcalf, J, Shaukat, S, Ninkovic, M, Shmueli, U, Davis, A, Naqvi, A, Lee, T, Ryder, S, Collier, J, Klass, H, Cramp, M, Sharer, N, Aspinall, R, Ghosh, D, Douds, A, Booth, J, Williams, E, Hussaini, H, Christie, J, Mann, S, Thorburn, D, Marshall, A, Patanwala, I, Ala, A, Maltby, J, Matthew, R, Corbett, C, Vyas, S, Singhal, S, Gleeson, D, Misra, S, Butterworth, J, George, K, Harding, T, Douglass, A, Mitchison, H, Panter, S, Shearman, J, Bray, G, Roberts, M, Butcher, G, Forton, D, Mahmood, Z, Cowan, M, Ch'Ng, C, Rahman, M, Whatley, G, Wesley, E, Mandal, A, Jain, S, Pereira, S, Wright, M, Trivedi, P, Gordon, F, Unitt, E, Palejwala, A, Austin, A, Vemala, V, Grant, A, Higham, A, Brind, A, Mathew, R, Cox, M, Ramakrishnan, S, King, A, Whalley, S, Fraser, J, Thomson, S, Bell, A, Wong, V, Kia, R, Gee, I, Keld, R, Ransford, R, Gotto, J, Millson, C, Tarocchi, M, Cordell H. J., Fryett J. J., Ueno K., Darlay R., Aiba Y., Hitomi Y., Kawashima M., Nishida N., Khor S. -S., Gervais O., Kawai Y., Nagasaki M., Tokunaga K., Tang R., Shi Y., Li Z., Juran B. D., Atkinson E. J., Gerussi A., Carbone M., Asselta R., Cheung A., de Andrade M., Baras A., Horowitz J., Ferreira M. A. R., Sun D., Jones D. E., Flack S., Spicer A., Mulcahy V. L., Byun J., Han Y., Sandford R. N., Lazaridis K. N., Amos C. I., Hirschfield G. M., Seldin M. F., Invernizzi P., Siminovitch K. A., Ma X., Nakamura M., Mells G. F., Mason A., Vincent C., Xie G., Zhang J., Affronti A., Almasio P. L., Alvaro D., Andreone P., Andriulli A., Azzaroli F., Battezzati P. M., Benedetti A., Bragazzi M. C., Brunetto M., Bruno S., Calvaruso V., Cardinale V., Casella G., Cazzagon N., Ciaccio A., Coco B., Colli A., Colloredo G., Colombo M., Colombo S., Cristoferi L., Cursaro C., Croce L. S., Crosignani A., D'Amato D., Donato F., Elia G., Fabris L., Fagiuoli S., Ferrari C., Floreani A., Galli A., Giannini E., Grattagliano I., Lampertico P., Lleo A., Malinverno F., Mancuso C., Marra F., Marzioni M., Massironi S., Mattalia A., Miele L., Milani C., Morini L., Morisco F., Muratori L., Muratori P., Niro G. A., O'Donnell S., Picciotto A., Portincasa P., Rigamonti C., Ronca V., Rosina F., Spinzi G., Strazzabosco M., Tiribelli C., Toniutto P., Valenti L., Vinci M., Zuin M., Nakamura H., Abiru S., Nagaoka S., Komori A., Yatsuhashi H., Ishibashi H., Ito M., Migita K., Ohira H., Katsushima S., Naganuma A., Sugi K., Komatsu T., Mannami T., Matsushita K., Yoshizawa K., Makita F., Nikami T., Nishimura H., Kouno H., Ota H., Komura T., Nakamura Y., Shimada M., Hirashima N., Komeda T., Ario K., Nakamuta M., Yamashita T., Furuta K., Kikuchi M., Naeshiro N., Takahashi H., Mano Y., Tsunematsu S., Yabuuchi I., Shimada Y., Yamauchi K., Sugimoto R., Sakai H., Mita E., Koda M., Tsuruta S., Kamitsukasa H., Sato T., Masaki N., Kobata T., Fukushima N., Ohara Y., Muro T., Takesaki E., Takaki H., Yamamoto T., Kato M., Nagaoki Y., Hayashi S., Ishida J., Watanabe Y., Kobayashi M., Koga M., Saoshiro T., Yagura M., Hirata K., Tanaka A., Takikawa H., Zeniya M., Abe M., Onji M., Kaneko S., Honda M., Arai K., Arinaga-Hino T., Hashimoto E., Taniai M., Umemura T., Joshita S., Nakao K., Ichikawa T., Shibata H., Yamagiwa S., Seike M., Honda K., Sakisaka S., Takeyama Y., Harada M., Senju M., Yokosuka O., Kanda T., Ueno Y., Kikuchi K., Ebinuma H., Himoto T., Yasunami M., Murata K., Mizokami M., Kawata K., Shimoda S., Miyake Y., Takaki A., Yamamoto K., Hirano K., Ichida T., Ido A., Tsubouchi H., Chayama K., Harada K., Nakanuma Y., Maehara Y., Taketomi A., Shirabe K., Soejima Y., Mori A., Yagi S., Uemoto S., H E., Tanaka T., Yamashiki N., Tamura S., Sugawara Y., Kokudo N., Chalasani N., Luketic V., Odin J., Chopra K., Abecasis G., Cantor M., Coppola G., Economides A., Lotta L. A., Overton J. D., Reid J. G., Shuldiner A., Beechert C., Forsythe C., Fuller E. D., Gu Z., Lattari M., Lopez A., Schleicher T. D., Padilla M. S., Toledo K., Widom L., Wolf S. E., Pradhan M., Manoochehri K., Ulloa R. H., Bai X., Balasubramanian S., Barnard L., Blumenfeld A., Eom G., Habegger L., Hawes A., Khalid S., Maxwell E. K., Salerno W., Staples J. C., Jones M. B., Mitnaul L. J., Sturgess R., Healey C., Yeoman A., Gunasekera A. V. J., Kooner P., Kapur K., Sathyanarayana V., Kallis Y., Subhani J., Harvey R., McCorry R., Rooney P., Ramanaden D., Evans R., Mathialahan T., Gasem J., Shorrock C., Bhalme M., Southern P., Tibble J. A., Gorard D. A., Jones S., Mells G., Mulcahy V., Srivastava B., Foxton M. R., Collins C. E., Elphick D., Karmo M., Porras-Perez F., Mendall M., Yapp T., Patel M., Ede R., Sayer J., Jupp J., Fisher N., Carter M. J., Koss K., Shah J., Piotrowicz A., Scott G., Grimley C., Gooding I. R., Williams S., Tidbury J., Lim G., Cheent K., Levi S., Mansour D., Beckley M., Hollywood C., Wong T., Marley R., Ramage J., Gordon H. M., Ridpath J., Ngatchu T., Bob Grover V. P., Shidrawi R. G., Abouda G., Corless L., Narain M., Rees I., Brown A., Taylor-Robinson S., Wilkins J., Grellier L., Banim P., Das D., Heneghan M. A., Curtis H., Matthews H. C., Mohammed F., Aldersley M., Srirajaskanthan R., Walker G., McNair A., Sharif A., Sen S., Bird G., Prince M. I., Prasad G., Kitchen P., Barnardo A., Oza C., Sivaramakrishnan N. N., Gupta P., Shah A., Evans C. D. J., Saha S., Pollock K., Bramley P., Mukhopadhya A., Barclay S. T., McDonald N., Bathgate A. J., Palmer K., Dillon J. F., Rushbrook S. M., Przemioslo R., McDonald C., Millar A., Tai C., Mitchell S., Metcalf J., Shaukat S., Ninkovic M., Shmueli U., Davis A., Naqvi A., Lee T. J. W., Ryder S., Collier J., Klass H., Cramp M. E., Sharer N., Aspinall R., Ghosh D., Douds A. C., Booth J., Williams E., Hussaini H., Christie J., Mann S., Thorburn D., Marshall A., Patanwala I., Ala A., Maltby J., Matthew R., Corbett C., Vyas S., Singhal S., Gleeson D., Misra S., Butterworth J., George K., Harding T., Douglass A., Mitchison H., Panter S., Shearman J., Bray G., Roberts M., Butcher G., Forton D., Mahmood Z., Cowan M., Ch'ng C. L., Rahman M., Whatley G. C. A., Wesley E., Mandal A., Jain S., Pereira S. P., Wright M., Trivedi P., Gordon F. H., Unitt E., Palejwala A., Austin A., Vemala V., Grant A., Higham A. D., Brind A., Mathew R., Cox M., Ramakrishnan S., King A., Whalley S., Fraser J., Thomson S. J., Bell A., Wong V. S., Kia R., Gee I., Keld R., Ransford R., Gotto J., Millson C., Tarocchi M., Cordell H. J., Cordell, H, Fryett, J, Ueno, K, Darlay, R, Aiba, Y, Hitomi, Y, Kawashima, M, Nishida, N, Khor, S, Gervais, O, Kawai, Y, Nagasaki, M, Tokunaga, K, Tang, R, Shi, Y, Li, Z, Juran, B, Atkinson, E, Gerussi, A, Carbone, M, Asselta, R, Cheung, A, de Andrade, M, Baras, A, Horowitz, J, Ferreira, M, Sun, D, Jones, D, Flack, S, Spicer, A, Mulcahy, V, Byun, J, Han, Y, Sandford, R, Lazaridis, K, Amos, C, Hirschfield, G, Seldin, M, Invernizzi, P, Siminovitch, K, Ma, X, Nakamura, M, Mells, G, Mason, A, Vincent, C, Xie, G, Zhang, J, Affronti, A, Almasio, P, Alvaro, D, Andreone, P, Andriulli, A, Azzaroli, F, Battezzati, P, Benedetti, A, Bragazzi, M, Brunetto, M, Bruno, S, Calvaruso, V, Cardinale, V, Casella, G, Cazzagon, N, Ciaccio, A, Coco, B, Colli, A, Colloredo, G, Colombo, M, Colombo, S, Cristoferi, L, Cursaro, C, Croce, L, Crosignani, A, D'Amato, D, Donato, F, Elia, G, Fabris, L, Fagiuoli, S, Ferrari, C, Floreani, A, Galli, A, Giannini, E, Grattagliano, I, Lampertico, P, Lleo, A, Malinverno, F, Mancuso, C, Marra, F, Marzioni, M, Massironi, S, Mattalia, A, Miele, L, Milani, C, Morini, L, Morisco, F, Muratori, L, Muratori, P, Niro, G, O'Donnell, S, Picciotto, A, Portincasa, P, Rigamonti, C, Ronca, V, Rosina, F, Spinzi, G, Strazzabosco, M, Tiribelli, C, Toniutto, P, Valenti, L, Vinci, M, Zuin, M, Nakamura, H, Abiru, S, Nagaoka, S, Komori, A, Yatsuhashi, H, Ishibashi, H, Ito, M, Migita, K, Ohira, H, Katsushima, S, Naganuma, A, Sugi, K, Komatsu, T, Mannami, T, Matsushita, K, Yoshizawa, K, Makita, F, Nikami, T, Nishimura, H, Kouno, H, Ota, H, Komura, T, Nakamura, Y, Shimada, M, Hirashima, N, Komeda, T, Ario, K, Nakamuta, M, Yamashita, T, Furuta, K, Kikuchi, M, Naeshiro, N, Takahashi, H, Mano, Y, Tsunematsu, S, Yabuuchi, I, Shimada, Y, Yamauchi, K, Sugimoto, R, Sakai, H, Mita, E, Koda, M, Tsuruta, S, Kamitsukasa, H, Sato, T, Masaki, N, Kobata, T, Fukushima, N, Ohara, Y, Muro, T, Takesaki, E, Takaki, H, Yamamoto, T, Kato, M, Nagaoki, Y, Hayashi, S, Ishida, J, Watanabe, Y, Kobayashi, M, Koga, M, Saoshiro, T, Yagura, M, Hirata, K, Tanaka, A, Takikawa, H, Zeniya, M, Abe, M, Onji, M, Kaneko, S, Honda, M, Arai, K, Arinaga-Hino, T, Hashimoto, E, Taniai, M, Umemura, T, Joshita, S, Nakao, K, Ichikawa, T, Shibata, H, Yamagiwa, S, Seike, M, Honda, K, Sakisaka, S, Takeyama, Y, Harada, M, Senju, M, Yokosuka, O, Kanda, T, Ueno, Y, Kikuchi, K, Ebinuma, H, Himoto, T, Yasunami, M, Murata, K, Mizokami, M, Kawata, K, Shimoda, S, Miyake, Y, Takaki, A, Yamamoto, K, Hirano, K, Ichida, T, Ido, A, Tsubouchi, H, Chayama, K, Harada, K, Nakanuma, Y, Maehara, Y, Taketomi, A, Shirabe, K, Soejima, Y, Mori, A, Yagi, S, Uemoto, S, H, E, Tanaka, T, Yamashiki, N, Tamura, S, Sugawara, Y, Kokudo, N, Chalasani, N, Luketic, V, Odin, J, Chopra, K, Abecasis, G, Cantor, M, Coppola, G, Economides, A, Lotta, L, Overton, J, Reid, J, Shuldiner, A, Beechert, C, Forsythe, C, Fuller, E, Gu, Z, Lattari, M, Lopez, A, Schleicher, T, Padilla, M, Toledo, K, Widom, L, Wolf, S, Pradhan, M, Manoochehri, K, Ulloa, R, Bai, X, Balasubramanian, S, Barnard, L, Blumenfeld, A, Eom, G, Habegger, L, Hawes, A, Khalid, S, Maxwell, E, Salerno, W, Staples, J, Jones, M, Mitnaul, L, Sturgess, R, Healey, C, Yeoman, A, Gunasekera, A, Kooner, P, Kapur, K, Sathyanarayana, V, Kallis, Y, Subhani, J, Harvey, R, Mccorry, R, Rooney, P, Ramanaden, D, Evans, R, Mathialahan, T, Gasem, J, Shorrock, C, Bhalme, M, Southern, P, Tibble, J, Gorard, D, Jones, S, Srivastava, B, Foxton, M, Collins, C, Elphick, D, Karmo, M, Porras-Perez, F, Mendall, M, Yapp, T, Patel, M, Ede, R, Sayer, J, Jupp, J, Fisher, N, Carter, M, Koss, K, Shah, J, Piotrowicz, A, Scott, G, Grimley, C, Gooding, I, Williams, S, Tidbury, J, Lim, G, Cheent, K, Levi, S, Mansour, D, Beckley, M, Hollywood, C, Wong, T, Marley, R, Ramage, J, Gordon, H, Ridpath, J, Ngatchu, T, Bob Grover, V, Shidrawi, R, Abouda, G, Corless, L, Narain, M, Rees, I, Brown, A, Taylor-Robinson, S, Wilkins, J, Grellier, L, Banim, P, Das, D, Heneghan, M, Curtis, H, Matthews, H, Mohammed, F, Aldersley, M, Srirajaskanthan, R, Walker, G, Mcnair, A, Sharif, A, Sen, S, Bird, G, Prince, M, Prasad, G, Kitchen, P, Barnardo, A, Oza, C, Sivaramakrishnan, N, Gupta, P, Shah, A, Evans, C, Saha, S, Pollock, K, Bramley, P, Mukhopadhya, A, Barclay, S, Mcdonald, N, Bathgate, A, Palmer, K, Dillon, J, Rushbrook, S, Przemioslo, R, Mcdonald, C, Millar, A, Tai, C, Mitchell, S, Metcalf, J, Shaukat, S, Ninkovic, M, Shmueli, U, Davis, A, Naqvi, A, Lee, T, Ryder, S, Collier, J, Klass, H, Cramp, M, Sharer, N, Aspinall, R, Ghosh, D, Douds, A, Booth, J, Williams, E, Hussaini, H, Christie, J, Mann, S, Thorburn, D, Marshall, A, Patanwala, I, Ala, A, Maltby, J, Matthew, R, Corbett, C, Vyas, S, Singhal, S, Gleeson, D, Misra, S, Butterworth, J, George, K, Harding, T, Douglass, A, Mitchison, H, Panter, S, Shearman, J, Bray, G, Roberts, M, Butcher, G, Forton, D, Mahmood, Z, Cowan, M, Ch'Ng, C, Rahman, M, Whatley, G, Wesley, E, Mandal, A, Jain, S, Pereira, S, Wright, M, Trivedi, P, Gordon, F, Unitt, E, Palejwala, A, Austin, A, Vemala, V, Grant, A, Higham, A, Brind, A, Mathew, R, Cox, M, Ramakrishnan, S, King, A, Whalley, S, Fraser, J, Thomson, S, Bell, A, Wong, V, Kia, R, Gee, I, Keld, R, Ransford, R, Gotto, J, Millson, C, Tarocchi, M, Cordell H. J., Fryett J. J., Ueno K., Darlay R., Aiba Y., Hitomi Y., Kawashima M., Nishida N., Khor S. -S., Gervais O., Kawai Y., Nagasaki M., Tokunaga K., Tang R., Shi Y., Li Z., Juran B. D., Atkinson E. J., Gerussi A., Carbone M., Asselta R., Cheung A., de Andrade M., Baras A., Horowitz J., Ferreira M. A. R., Sun D., Jones D. E., Flack S., Spicer A., Mulcahy V. L., Byun J., Han Y., Sandford R. N., Lazaridis K. N., Amos C. I., Hirschfield G. M., Seldin M. F., Invernizzi P., Siminovitch K. A., Ma X., Nakamura M., Mells G. F., Mason A., Vincent C., Xie G., Zhang J., Affronti A., Almasio P. L., Alvaro D., Andreone P., Andriulli A., Azzaroli F., Battezzati P. M., Benedetti A., Bragazzi M. C., Brunetto M., Bruno S., Calvaruso V., Cardinale V., Casella G., Cazzagon N., Ciaccio A., Coco B., Colli A., Colloredo G., Colombo M., Colombo S., Cristoferi L., Cursaro C., Croce L. S., Crosignani A., D'Amato D., Donato F., Elia G., Fabris L., Fagiuoli S., Ferrari C., Floreani A., Galli A., Giannini E., Grattagliano I., Lampertico P., Lleo A., Malinverno F., Mancuso C., Marra F., Marzioni M., Massironi S., Mattalia A., Miele L., Milani C., Morini L., Morisco F., Muratori L., Muratori P., Niro G. A., O'Donnell S., Picciotto A., Portincasa P., Rigamonti C., Ronca V., Rosina F., Spinzi G., Strazzabosco M., Tiribelli C., Toniutto P., Valenti L., Vinci M., Zuin M., Nakamura H., Abiru S., Nagaoka S., Komori A., Yatsuhashi H., Ishibashi H., Ito M., Migita K., Ohira H., Katsushima S., Naganuma A., Sugi K., Komatsu T., Mannami T., Matsushita K., Yoshizawa K., Makita F., Nikami T., Nishimura H., Kouno H., Ota H., Komura T., Nakamura Y., Shimada M., Hirashima N., Komeda T., Ario K., Nakamuta M., Yamashita T., Furuta K., Kikuchi M., Naeshiro N., Takahashi H., Mano Y., Tsunematsu S., Yabuuchi I., Shimada Y., Yamauchi K., Sugimoto R., Sakai H., Mita E., Koda M., Tsuruta S., Kamitsukasa H., Sato T., Masaki N., Kobata T., Fukushima N., Ohara Y., Muro T., Takesaki E., Takaki H., Yamamoto T., Kato M., Nagaoki Y., Hayashi S., Ishida J., Watanabe Y., Kobayashi M., Koga M., Saoshiro T., Yagura M., Hirata K., Tanaka A., Takikawa H., Zeniya M., Abe M., Onji M., Kaneko S., Honda M., Arai K., Arinaga-Hino T., Hashimoto E., Taniai M., Umemura T., Joshita S., Nakao K., Ichikawa T., Shibata H., Yamagiwa S., Seike M., Honda K., Sakisaka S., Takeyama Y., Harada M., Senju M., Yokosuka O., Kanda T., Ueno Y., Kikuchi K., Ebinuma H., Himoto T., Yasunami M., Murata K., Mizokami M., Kawata K., Shimoda S., Miyake Y., Takaki A., Yamamoto K., Hirano K., Ichida T., Ido A., Tsubouchi H., Chayama K., Harada K., Nakanuma Y., Maehara Y., Taketomi A., Shirabe K., Soejima Y., Mori A., Yagi S., Uemoto S., H E., Tanaka T., Yamashiki N., Tamura S., Sugawara Y., Kokudo N., Chalasani N., Luketic V., Odin J., Chopra K., Abecasis G., Cantor M., Coppola G., Economides A., Lotta L. A., Overton J. D., Reid J. G., Shuldiner A., Beechert C., Forsythe C., Fuller E. D., Gu Z., Lattari M., Lopez A., Schleicher T. D., Padilla M. S., Toledo K., Widom L., Wolf S. E., Pradhan M., Manoochehri K., Ulloa R. H., Bai X., Balasubramanian S., Barnard L., Blumenfeld A., Eom G., Habegger L., Hawes A., Khalid S., Maxwell E. K., Salerno W., Staples J. C., Jones M. B., Mitnaul L. J., Sturgess R., Healey C., Yeoman A., Gunasekera A. V. J., Kooner P., Kapur K., Sathyanarayana V., Kallis Y., Subhani J., Harvey R., McCorry R., Rooney P., Ramanaden D., Evans R., Mathialahan T., Gasem J., Shorrock C., Bhalme M., Southern P., Tibble J. A., Gorard D. A., Jones S., Mells G., Mulcahy V., Srivastava B., Foxton M. R., Collins C. E., Elphick D., Karmo M., Porras-Perez F., Mendall M., Yapp T., Patel M., Ede R., Sayer J., Jupp J., Fisher N., Carter M. J., Koss K., Shah J., Piotrowicz A., Scott G., Grimley C., Gooding I. R., Williams S., Tidbury J., Lim G., Cheent K., Levi S., Mansour D., Beckley M., Hollywood C., Wong T., Marley R., Ramage J., Gordon H. M., Ridpath J., Ngatchu T., Bob Grover V. P., Shidrawi R. G., Abouda G., Corless L., Narain M., Rees I., Brown A., Taylor-Robinson S., Wilkins J., Grellier L., Banim P., Das D., Heneghan M. A., Curtis H., Matthews H. C., Mohammed F., Aldersley M., Srirajaskanthan R., Walker G., McNair A., Sharif A., Sen S., Bird G., Prince M. I., Prasad G., Kitchen P., Barnardo A., Oza C., Sivaramakrishnan N. N., Gupta P., Shah A., Evans C. D. J., Saha S., Pollock K., Bramley P., Mukhopadhya A., Barclay S. T., McDonald N., Bathgate A. J., Palmer K., Dillon J. F., Rushbrook S. M., Przemioslo R., McDonald C., Millar A., Tai C., Mitchell S., Metcalf J., Shaukat S., Ninkovic M., Shmueli U., Davis A., Naqvi A., Lee T. J. W., Ryder S., Collier J., Klass H., Cramp M. E., Sharer N., Aspinall R., Ghosh D., Douds A. C., Booth J., Williams E., Hussaini H., Christie J., Mann S., Thorburn D., Marshall A., Patanwala I., Ala A., Maltby J., Matthew R., Corbett C., Vyas S., Singhal S., Gleeson D., Misra S., Butterworth J., George K., Harding T., Douglass A., Mitchison H., Panter S., Shearman J., Bray G., Roberts M., Butcher G., Forton D., Mahmood Z., Cowan M., Ch'ng C. L., Rahman M., Whatley G. C. A., Wesley E., Mandal A., Jain S., Pereira S. P., Wright M., Trivedi P., Gordon F. H., Unitt E., Palejwala A., Austin A., Vemala V., Grant A., Higham A. D., Brind A., Mathew R., Cox M., Ramakrishnan S., King A., Whalley S., Fraser J., Thomson S. J., Bell A., Wong V. S., Kia R., Gee I., Keld R., Ransford R., Gotto J., Millson C., and Tarocchi M.

Abstract

It has come to our attention that the name of one of the authors in our manuscript was incorrectly spelled ‘Jinyoung Byan’; the correct spelling is ‘Jinyoung Byun’ as in the author list above. In addition, the excel files of the supplementary tables were not included during the online publication of our article. These have now been made available online. We apologize for any inconvenience caused.

Published
2022

29. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study

Author

Valenti, L, Pelusi, S, Aghemo, A, Gritti, S, Pasulo, L, Bianco, C, Iegri, C, Cologni, G, Degasperi, E, D'Ambrosio, R, del Poggio, P, Soria, A, Puoti, M, Carderi, I, Pigozzi, M, Carriero, C, Spinetti, A, Zuccaro, V, Memoli, M, Giorgini, A, Vigano, M, Rumi, M, Re, T, Spinelli, O, Colombo, M, Quirino, T, Menzaghi, B, Lorini, G, Pan, A, D'Arminio Monforte, A, Buscarini, E, Autolitano, A, Bonfanti, P, Terreni, N, Aimo, G, Mendeni, M, Prati, D, Lampertico, P, Fagiuoli, S, Valenti L., Pelusi S., Aghemo A., Gritti S., Pasulo L., Bianco C., Iegri C., Cologni G., Degasperi E., D'Ambrosio R., del Poggio P., Soria A., Puoti M., Carderi I., Pigozzi M. G., Carriero C., Spinetti A., Zuccaro V., Memoli M., Giorgini A., Vigano M., Rumi M. G., Re T., Spinelli O., Colombo M. C., Quirino T., Menzaghi B., Lorini G., Pan A., D'Arminio Monforte A., Buscarini E., Autolitano A., Bonfanti P., Terreni N., Aimo G., Mendeni M., Prati D., Lampertico P., Colombo M., Fagiuoli S., Valenti, L, Pelusi, S, Aghemo, A, Gritti, S, Pasulo, L, Bianco, C, Iegri, C, Cologni, G, Degasperi, E, D'Ambrosio, R, del Poggio, P, Soria, A, Puoti, M, Carderi, I, Pigozzi, M, Carriero, C, Spinetti, A, Zuccaro, V, Memoli, M, Giorgini, A, Vigano, M, Rumi, M, Re, T, Spinelli, O, Colombo, M, Quirino, T, Menzaghi, B, Lorini, G, Pan, A, D'Arminio Monforte, A, Buscarini, E, Autolitano, A, Bonfanti, P, Terreni, N, Aimo, G, Mendeni, M, Prati, D, Lampertico, P, Fagiuoli, S, Valenti L., Pelusi S., Aghemo A., Gritti S., Pasulo L., Bianco C., Iegri C., Cologni G., Degasperi E., D'Ambrosio R., del Poggio P., Soria A., Puoti M., Carderi I., Pigozzi M. G., Carriero C., Spinetti A., Zuccaro V., Memoli M., Giorgini A., Vigano M., Rumi M. G., Re T., Spinelli O., Colombo M. C., Quirino T., Menzaghi B., Lorini G., Pan A., D'Arminio Monforte A., Buscarini E., Autolitano A., Bonfanti P., Terreni N., Aimo G., Mendeni M., Prati D., Lampertico P., Colombo M., and Fagiuoli S.

Abstract

The aim of this study was to examine the impact of features of dysmetabolism on liver disease severity, evolution, and clinical outcomes in a real-life cohort of patients treated with direct acting antivirals for chronic hepatitis C virus (HCV) infection. To this end, we considered 7,007 patients treated between 2014 and 2018, 65.3% with advanced fibrosis, of whom 97.7% achieved viral eradication (NAVIGATORE-Lombardia registry). In a subset (n = 748), liver stiffness measurement (LSM) was available at baseline and follow-up. Higher body mass index (BMI; odds ratio [OR] 1.06 per kg/m2, 1.03-1.09) and diabetes (OR 2.01 [1.65-2.46]) were independently associated with advanced fibrosis at baseline, whereas statin use was protective (OR 0.46 [0.35-0.60]; P < 0.0001 for all). The impact of BMI was greater in those without diabetes (P = 0.003). Diabetes was independently associated with less pronounced LSM improvement after viral eradication (P = 0.001) and in patients with advanced fibrosis was an independent predictor of the most frequent clinical events, namely de novo hepatocellular carcinoma (HCC; hazard ratio [HR] 2.09 [1.20-3.63]; P = 0.009) and cardiovascular events (HR 2.73 [1.16-6.43]; P = 0.021). Metformin showed a protective association against HCC (HR 0.32 [0.11-0.96]; P = 0.043), which was confirmed after adjustment for propensity score (P = 0.038). Diabetes diagnosis further refined HCC prediction in patients with compensated advanced chronic liver disease at high baseline risk (P = 0.024). Conclusion: Metabolic comorbidities were associated with advanced liver fibrosis at baseline, whereas statins were protective. In patients with advanced fibrosis, diabetes increased the risk of de novo HCC and of cardiovascular events. Optimization of metabolic comorbidities treatment by a multi-disciplinary management approach may improve cardiovascular and possibly liver-related

Published
2022

31. A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms

Author

Sharkawy, Rasha El, Bayoumi, Ali, Metwally, Mayada, Mangia, Alessandra, Berg, Thomas, Romero-Gomez, Manuel, Abate, Maria Lorena, Irving, William L., Sheridan, David, Dore, Gregory J., Spengler, Ulrich, Lampertico, Pietro, Bugianesi, Elisabetta, Weltman, Martin, Mollison, Lindsay, Cheng, Wendy, Riordan, Stephen, Santoro, Rosanna, Gallego-Durán, Rocío, Fischer, Janett, Nattermann, Jacob, D’Ambrosio, Roberta, McLeod, Duncan, Powell, Elizabeth, latchoumanin, Olivier, Thabet, Khaled, Najim, Mustafa A. M., Douglas, Mark W., Liddle, Christopher, Qiao, Liang, George, Jacob, Eslam, Mohammed, and International Liver Disease Genetics Consortium (ILDGC)

Published
2019
Full Text
View/download PDF

32. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals

Author

Pelusi, S, Bianco, C, Colombo, M, Cologni, G, Del Poggio, P, Pugliese, N, Prati, D, Pigozzi, M, D'Ambrosio, R, Lampertico, P, Fagiuoli, S, Valenti, L, Pelusi, Serena, Bianco, Cristiana, Colombo, Massimo, Cologni, Giuliana, Del Poggio, Paolo, Pugliese, Nicola, Prati, Daniele, Pigozzi, Marie Graciella, D'Ambrosio, Roberta, Lampertico, Pietro, Fagiuoli, Stefano, Valenti, Luca, Pelusi, S, Bianco, C, Colombo, M, Cologni, G, Del Poggio, P, Pugliese, N, Prati, D, Pigozzi, M, D'Ambrosio, R, Lampertico, P, Fagiuoli, S, Valenti, L, Pelusi, Serena, Bianco, Cristiana, Colombo, Massimo, Cologni, Giuliana, Del Poggio, Paolo, Pugliese, Nicola, Prati, Daniele, Pigozzi, Marie Graciella, D'Ambrosio, Roberta, Lampertico, Pietro, Fagiuoli, Stefano, and Valenti, Luca

Abstract

Background and Aims: Metabolic dysfunction (MD)-associated fatty liver disease has been proposed to identify individuals at risk of liver events irrespectively of the contemporary presence of other liver diseases. The aim of this study was to examine the impact of MD in patients cured of chronic hepatis C (CHC). Patients and Methods: We analysed data from a real-life cohort of 2611 Italian patients cured of CHC with direct antiviral agents and advanced liver fibrosis, without HBV/HIV, transplantation and negative for hepatocellular carcinoma (HCC) history (age 61.4 ± 11.8 years, 63.9% males, median follow-up 34, 24–40 months). Information about ultrasonographic steatosis (US) after sustained virological response was available in 1978. Results: MD affected 58% of patients, diagnosed due to the presence of diabetes (MD-diabetes, 19%), overweight without diabetes (MD-overweight, 37%) or multiple metabolic abnormalities without overweight and diabetes (MD-metabolic, 2%). MD was more frequent than and not coincident with US (32% MD-only, 23% MD-US and 13% US-only). MD was associated with higher liver stiffness (p < 0.05), particularly in patients with MD-diabetes and MD-only subgroups, comprising older individuals with more advanced metabolic and liver disease (p < 0.05). At Cox proportional hazard multivariable analysis, MD was associated with increased risk of HCC (HR 1.97, 95% CI 1.27–3.04; p = 0.0023). Further classification according to diagnostic criteria improved risk stratification (p < 0.0001), with the highest risk observed in patients with MD-diabetes. Patients with MD-only appeared at highest risk since the sustained virological response achievement (p = 0.008), with a later catch-up of those with combined MD-US, whereas US-only was not associated with HCC. Conclusions: MD is more prevalent than US in patients cured of CHC with advanced fibrosis and identifies more accurately individuals at risk of developing HCC.

Published
2023

33. Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.

Author

Farina, E, Loglio, A, Tosetti, G, Degasperi, E, Viganò, M, Gentile, C, Monico, S, Perbellini, R, Borghi, M, Facchetti, F, Uceda Renteria, SC, Ceriotti, F, Cerini, F, Primignani, M, Lampertico, P, Farina, E, Loglio, A, Tosetti, G, Degasperi, E, Viganò, M, Gentile, C, Monico, S, Perbellini, R, Borghi, M, Facchetti, F, Uceda Renteria, SC, Ceriotti, F, Cerini, F, Primignani, M, and Lampertico, P

Abstract

BACKGROUND: Long-term administration of TDF/ETV in patients with HBV-related compensated cirrhosis reduces HCC and decompensation events but the effect of this regimen on development/regression of oesophageal varices (EV) is currently unknown. AIM: To assess the risk of EV development/progression in this population. METHODS: A total of 186 Caucasian HBV-monoinfected compensated cirrhotics were enrolled in a long-term cohort study from TDF/ETV introduction. Upper GI endoscopies were performed according to Baveno recommendations. Primary endpoint was development/progression of oesophageal/gastric varices over time. RESULTS: At TDF/ETV start, median age was 61 years, 80% males, 60% HBV-DNA undetectable, 63% NUCs previously exposed, 73% normal ALT, 40% platelets <150,000/mmc and 25 (13%) with low-risk varices (LRV). During 11 years of antiviral therapy and 666 endoscopies performed, 9 patients either developed or had a progression of oesophageal or gastric varices with an 11-year cumulative probability of 5.1% (95% CI 3-10%); no patient bled. Out of 161 patients without EV at baseline, the 11-year probably was 4.5% with all varices developing within the first six years of treatment. In 25 patients with LRV at baseline, the 11-year probability of progression or regression was 9.3% and 58%, respectively. Only baseline platelet count (HR 0.96, p = 0.028) was associated with LRV development at multivariate analysis: platelet ≤90,000/mmc (AUROC 0.70) had 98.1% specificity, 42.9% sensitivity, 50% PPV for LRV onset. CONCLUSIONS: In compensated cirrhotic patients under long-term effective TDF/ETV treatment, the 11-year risk of developing/progressing EV is negligible, thus challenging the current endoscopic surveillance recommendations in patients without EV at baseline.

Published
2023

34. Similar Rates of Biochemical Response Are Observed Across Virologic Response Categories Over 96 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta.

Author

Lampertico, P., Asselah, T., Chulanov, V., Bogomolov, P., Stepanova, T., Cornberg, M., Manuilov, D., Li, M., Lau, A.H., Da, B.L., Tedesco, D., Chee, G.M., Brunetto, M.R., Zeuzem, S., Zoulim, F., Wedemeyer, H., and Aleman, S.

Abstract

Bulevirtide (BLV) is approved for treatment for chronic hepatitis delta (CHD) in Europe. BLV is not a direct antiviral but prevents liver spreading of HDV; biochemical response (BR; alanine aminotransferase [ALT] normalisation) can be observed independently of virologic response (VR) likely due to prevention of de novo infection of hepatocytes. Previous analyses using 48-week (W) treatment data described similar rates of BR across multiple HDV RNA response cutoffs. We examined whether this effect persists beyond 48W of BLV monotherapy. Pooled W96 BLV (2mg/day, 10mg/day) data from 2 clinical studies were analysed. VR categories included log10 declines from baseline (BL), undetectable HDV RNA, and absolute value HDV RNA cutoffs (1000–10,000 IU/mL). ALT response (ALT ≤ upper limit of normal [ULN] or ALT ≤1.5 × ULN) was evaluated in each VR category. Included were 190 patients with CHD (BLV 2mg, n=47; BLV 10mg, n=143). After 96W of BLV monotherapy, 34% to 90% of patients achieved VR across the VR categories (Figure); 85% had VR (HDV RNA undetectable or ≥2-log10 decline from BL in HDV RNA). ALT ≤ULN or ≤1.5 × ULN was achieved by 64% and 83% of patients, respectively. Proportions achieving VR were similar: 88% of patients with ALT ≤ULN and 89% with ALT ≤1.5 × ULN. HDV RNA <10,000 IU/mL was the most inclusive metric for detecting ALT response, capturing 94% of those with ALT ≤ULN and 94% of those with ALT ≤1.5 × ULN. The proportions of patients with VR with or without BR were similar regardless of the VR cutoff. The use of a less stringent cutoff for VR (ie, HDV RNA <10,000 IU/mL) over the standard VR definition can capture additional cases of ALT response. Like previous findings, similar rates of ALT responses were observed across the evaluated VR subgroups after 96W of BLV monotherapy. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

35. More advanced presentation but similar survival for hepatocellular carcinoma in HIV positive compared to HIV-negative patients: a retrospective cohort analysis.

Author

Iavarone, M., Alimenti, E., Puoti, M., Hasson, H., Monti, B., Peracchi, F., Siribelli, A., Fava, M., Bruccoleri, M., Merli, M., Morsica, G., De Silvestri, A., Bonfanti, P., Castagna, A., Soria, A., and Lampertico, P.

Abstract

Conflicting data on survival of people with HIV (PWH) who develop hepatocellular carcinoma (HCC) could depend on inequal access to curative treatments. We compared two cohorts of patients with HCC, HIV-positive and negative. Patients from four referral centers, with a first HCC diagnosis (01/2005-03/2024) were included in a retrospective analysis. Clinical characteristics, access to treatment and survival (OS) were described, according to HIV status. Cox regression models were used to identify predictors of mortality and recurrence. Inverse probability weighting (IPW) and propensity score (PS) methods were used to estimate the HIV-status effect. 606 patients were enrolled (143 PWH, 463 HIV-negative): PWH were younger (53 vs 68 years, p<0.001), mainly males (87% vs 75%, p=0.004), prevalent viral etiology (99% vs 77%), less frequently Child-Pugh A (71% vs 76%, p=0.01). PWH had a higher proportion of advanced Barcelona Clinical Liver Cancer (BCLC) stage (22% vs 10%, p<0.001), and higher rates of AFP>200 ng/mL (28% vs 15%, p=0.001), macrovascular invasion and/or extrahepatic spread (27% vs 11%, p<0.001), despite similar rate of surveillance (91% vs 88%). Median follow-up was 32 (11-78) months for PWH and 36 (19-84) for HIV-negative. The 5-year OS rate was 43.4% for PWH vs 44.1% in HIV-negative (log rank p=0.97). Independent predictors of mortality in PWH were: presence of esophagogastric varices (HR 2.45, 95%CI 1.16-5.15, p=0.02), AFP >200 ng/mL (HR 3.13, 95%CI 1.73-5.70, p<0.001), advanced/end-stage HCC (C: HR 5.74, 95%CI 1.93-17.08, p=0.002; D: HR 16.73, 95%CI 3.59-78.03, p<0.001) and no active treatment (HR 5.86, 95%CI 1.20-28.49, p=0.03). After IPWT/PS, PWH showed higher 2-year recurrence rate (47.39% [95%CI 32.6-64.9] vs 22.8% [95%CI 17.6-29.2], p=0.03). Overall survival was similar in PWH and HIV-negative individuals with HCC, despite more advanced tumors at presentation and higher recurrence rates: aggressive downstaging strategies to provide curative options granted prolonged survival. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

36. A peculiar composition of HBsAg isoforms characterizes chronic HDV coinfection respect to HBV mono-infection with higher middle- and large-HBs levels reflecting a more intense HDV activity.

Author

Magnapera, A., Piermatteo, L., D'Anna, S., Olivero, A., Duca, L., Torre, G., Castelli, C., Teti, E., Lorenzo, A. Di, Malagnino, V., Iannetta, M., Baiocchi, L., Francioso, S., Lenci, I., Ceccherini-Silberstein, F., Milella, M., Saracino, A., Ciancio, A., Sarmati, L., and Lampertico, P.

Abstract

HBV surface proteins (HBsAg) drive HBV and HDV entry and morphogenesis. Total HBsAg comprises 3 different forms: Large- (L-HBs), Middle- (M-HBs) and Small-HBs (S-HBs) with L-HBs found in virions rather than subviral particles. Te investigate the levels of HBs isoforms in the setting of chronic HBV mono-infection (CHB) and HDV coinfection (CHD). This study includes 262 plasma samples from HBeAg-negative patients: 143 CHD and 119 CHB. Total HBsAg is measured by COBAS HBsAg II assays (Roche), HBs forms by ad-hoc designed ELISAs (Beacle) and HDV-RNA was quantified by Robogene assay. CHD and CHB patients have comparable age and rate of NUC treatment. CHD have lower HBV-DNA (median [IQR]: 1.3[0.0-2.3], 1.6[1.2-3.4] logIU/ml; P=0.002), higher ALT (median[IQR]: 79[50-113], 36[22-63]U/L; P<0.001) and total HBsAg levels (median[IQR]: 5206[827-8555], 1776[354-6936]IU/ml; P=0.008). Median(IQR) HDV-RNA is 5.2 (3.4-6.0)logIU/ml. CHD correlate with higher M- and L-HBs respect to CHB (median[IQR]: 1127[145-2301] vs 142[25-707] and 2.0[0.2-6.3] vs 0.06[0.2-0.5]ng/ml); P<0.001), despite similar S-HBs levels (median [IQR]: 3221[587-6497], 1039[239-5438]ng/ml). Datum confirmed by multivariable analysis (OR[95%CI]: 4.7[1.7-12-4], 6.2[2.2-17.9]; P<0.002). Among CHD, HBs forms positively correlate with HDV-RNA levels (Rho=0.48, 0.49, 0.43 for S-/M-/L-HBs; P<0.001) while in CHB, L-HBs correlates weakly with HBV-DNA levels (Rho=0.29, 0.02). Patients with HDV-RNA>3log U/ml show significantly higher levels of all HBs forms than lowly-replicating HDV (median[IQR]ng/ml: 4431[1251-6950] vs 274[25-2640] for S-HBs; 1404[191-2484] vs127[4-1242] for M-HBs; 3.3[0.2-7.8] vs 0.3[0.04-1.1] for L-HBs; P<0.001 for all). M-HBs>200ng/ml is the best cut-off predicting altered ALT (70% M-HBs>200ng/ml vs 30% M-HBs<200ng/ml has ALT>40U/L; PPV=70%, NPV=76.9%; P=0.04). HBsAg form composition differs in CHD vs CHB, with CHD showing higher M-HBs and L-HBs, along with HDV replication, potentially reflecting a variation in the proportion of circulating viral and subviral particles for CHD and CHB. Overall, HBs forms can aid in prioritizing treatment against liver disease progression. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

37. A multicenter analysis on efficacy and safety of Tenofovir alafenamide (TAF) in a wide cohort of patients with chronic hepatitis B (CHB).

Author

Tizzani, M., Caviglia, GP., Frasson, A., Degasperi, E., Viganò, M., Borghi, M., Sambarino, D., Loglio, A., Farina, E., Fagiuoli, S., Lampertico, P., and Marzano, A.

Abstract

First (Lamivudine-LAM), second (Telbivudin, Adefovir-ADV), and third (Tenofovir-TDF, Entecavir) generation Nucleos(t)ide analogues (NAs) changed the natural history of CHB, leading to high rates of virological suppression, despite a not negligible risk of virologic resistance and nephrotoxicity (mostly ADV and TDF). To investigate clinical and virological outcomes of patients treated with TAF, the most recent NA approved for HBV therapy. We retrospectively enrolled 381 patients with CHB (median age: 72, IQR 66–77 years; males: 69.3%; liver cirrhosis: 38.3%) treated with TAF (median treatment duration: 3.7, IQR 2.5–4.5 years) in three Northern-Italian centers. Data were collected at TAF introduction (T0) and last follow-up (FU). Median NAs treatment duration before TAF initiation was 15.5 (12.5–18.3) years (LAM: 317, 83.4%; ADV: 215, 56.4%; LAM+ADV: 190, 49.9%). Thirteen (4.3%) patients had previous kidney transplant, 175 (45.9%) had chronic kidney disease and 190 (49.9%) needed NAs dose reduction due to renal impairment. The main indications for switching to TAF were age >60 years, virologic resistance, and Reduced glomerular filtration rate (GFR). From T0 to last FU, we did not observe any variation in creatinine values (1.10, 0.90–1.30 mg/dL vs 1.09, 0.90 – 1.30 mg/dL; p=0.660) and GFR-MDRD4 (66.9, 52.4–80.9 mL/min vs 66.1, 52.8–80.6 ml/min; p=0.470), while ALT values further decreased from 21 (17–27) U/L to 20 (15–26) U/L (p<0.001). At T0, 361 (94.7%) were HBV-DNA-negative, and none had a virological relapse; for the other 20 (5.3%) viremic patients, only 4 were still HBV-DNA-positive at last FU (2 of whom had FU<4 months). During TAF, 8 (2.4%) patients had de-novo HCC, and 33 (8.7%) died, mostly for non-liver-related causes (60.6%). TAF treatment was effective in inducing and maintaining virologic and biochemical remission. No significant safety concerns were observed in patients with renal impairment. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

38. Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Eurobioplex EBX071 and Altostar.

Author

Anolli, M.P., Renteria, S. Uceda, Degasperi, E., Facchetti, F., Sambarino, D., Borghi, M., Perbellini, R., Soffredini, R., Monico, S., Callegaro, A., and Lampertico, P.

Abstract

Accurate quantification of HDV-RNA is essential for diagnosing and managing chronic hepatitis Delta (CHD), but there is considerable variability between different assays. In this study, we compared three methods for HDV-RNA quantification in both untreated and Bulevirtide (BLV)-treated CHD patients. Frozen plasma samples from untreated and BLV–treated CHD patients were tested in a single-center retrospective study by 3 different assays: Robogene HDV-RNA Quantification Kit 2.0 [Roboscreen GmbH; Lower Limit of Detection (LOD) <6 IU/mL, Lower Limit of Quantification (LOQ) 60 IU/mL on 7500 Fast Real-Time PCR System (Applied Byosystem)], EurobioPlex HDV PCR quantitative EBX071 [Eurobio Scientific, LOD <20 UI/mL, LOQ 50 UI/mL on CFX96™ real-time PCR detection system (Bio-Rad)] and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics, estimated LOD <10 IU/mL estimated LOQ 20 UI/mL on AltoStar®AM16). 112 plasma samples from 79 CHD (10 untreated and 69 BLV-treated) patients were studied by 3 different assays (total 336 tests). All patients were HDV genotype 1 (available in 70). Median HDV RNA was 3.05 (-0.04-6.69) Log IU/mL with Robogene 2.0, 3.78 (-0.83-7.78) IU/mL with EurobioPlex EBX071, 3.22 (-0.31-7.03) IU/mL with AltoStar (Robogene vs. EurobioPlex p=0.005; Robogene vs. AltoStar p<0.0001; EurobioPlex vs. AltoStar p=0.5; overall p<0.0001). Compared to Robogene 2.0, EurobioPlex EBX071 reported higher (>0.5 Log IU/mL) HDV RNA levels in 33% samples, similar levels (<±0.5 Log IU/mL) in 55%. Likewise, compared to Robogene 2.0, AltoStar reported higher HDV RNA levels in 18% of positive samples, similar levels in 82%. Robogene tested target not detected (TND) or

Published
2025
Full Text
View/download PDF

39. Prevalence of HBV and HCV infections among at-risk migrant and refugee populations in Italy: 2-year results of the VH-COMSAVAC European project.

Author

Colucci, G., Sguazzini, E., Damonte, R., Romanò, G., Spada, A., Cassola, R., and Lampertico, P.

Abstract

VH-COMSAVAC is a European project, co-funded by the European Commission and involving institutions in Greece, Italy and Spain, to offer community-based HBV and HCV testing, HBV vaccination, and linkage-to-care strategies to migrant and refugee populations from countries with high HBV and HCV prevalence. The project is based on simplified tools and person-centered referral processes, to ultimately reduce liver cancer-associated mortality. Decentralized HBV and HCV testing was offered in community and faith-based organizations using HBV surface antigen (HBsAg) and anti-HCV rapid diagnostic tests (RDTs). Participants with a positive RDT were referred to our clinics to confirm an active infection and start appropriate anti-viral treatment. To date 423 individuals have been recruited and screened for HBV and/or HCV, 56% men, with a median age of 47 years (18-79). Overall HBsAg+ and anti-HCV+ prevalence was 1.7% and 2.1%, respectively. Most participants were born in Latin America (40%) followed by North Africa (19%), Central Africa (12%), Asia (13%) and Eastern Europe (8%). Of the 7 HBsAg+ individuals 2 originated from Bangladesh and the remaining from China, Dominican Republic, Ghana, Romania and Senegal. Among anti-HCV+ participants 5 were from Egypt and the remaining from Colombia, Pakistan, Russia and Ukraine. Among positive participants, three (23%) were linked to care, and 13 are in the process of being admitted to our clinics. VH-COMSAVAC has been successful in screening at-risk migrant and refugee populations in Italy, supporting the HCV and HBV micro-elimination strategy based on fragile populations migrating from high prevalence countries. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

40. Omicron SARS-CoV-2 variant outbreak in vaccinated liver transplant (LT) recipients in 2022: A large spread of infection, a mild disease

Author

Donato, M.F., primary, Dibenedetto, C., additional, Farina, E., additional, Toppetta, A., additional, Renteria, S.C. Uceda, additional, Rigamonti, C., additional, Antonelli, B., additional, Caccamo, L., additional, Lombardi, A., additional, Bandera, A., additional, Ceriotti, F., additional, and Lampertico, P., additional

Published
2023
Full Text
View/download PDF

41. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data

Author

Asselah, T., primary, Lampertico, P., additional, Aleman, S., additional, Bourliere, M., additional, Streinu-Cercel, A., additional, Bogomolov, P., additional, Morozov, V., additional, Stepanova, T., additional, Lazar, S., additional, Suri, V., additional, Manuilov, D., additional, Mercier, R.C., additional, Tseng, S., additional, Ye, L., additional, Flaherty, J.F., additional, Osinusi, A., additional, Brunetto, M., additional, and Wedemeyer, H., additional

Published
2023
Full Text
View/download PDF

42. Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib

Author

Iavarone, M., primary, Alimenti, E., additional, Tada, T., additional, Shimose, S., additional, Suda, G., additional, Yoo, C., additional, Soldà, C., additional, Piscaglia, F., additional, Casadei-Gardini, A., additional, Marra, F., additional, Vivaldi, C., additional, Conti, F., additional, Schirripa, M., additional, Iwamoto, H., additional, Sho, T., additional, Lee, So Heun, additional, Rizzato, M.D., additional, Tonnini, M., additional, Rimini, M., additional, Campani, C., additional, Masi, G., additional, Foschi, F., additional, Bruccoleri, M., additional, Kawaguchi, T., additional, Kumada, T., additional, Hiraoka, A., additional, Atsukawa, M., additional, Fukunishi, S., additional, Ishikawa, T., additional, Tajiri, K., additional, Ochi, H., additional, Yasuda, S., additional, Toyoda, H., additional, Hatanaka, T., additional, Kakizaki, S., additional, Kawata, K., additional, Tada, F., additional, Ohama, H., additional, Itokawa, N., additional, Okubo, T., additional, Arai, T., additional, Imai, M., additional, Naganuma, A., additional, Tosetti, G., additional, and Lampertico, P., additional

Published
2023
Full Text
View/download PDF

43. RESIST Criteria: A biochemical algorithm to reduce the number of unnecessary upper endoscopies for the evaluation of portal hypertension in compensated HBV-cirrhotic patients

Author

Calvaruso, V., primary, Celsa, C., additional, Degasperi, E., additional, Di Maria, G., additional, Fichera, A., additional, Graceffa, P., additional, Rancatore, G., additional, Falco, G., additional, Di Martino, V., additional, Rizzo, G.E.M., additional, Grasso, M., additional, Bronte, F., additional, Simone, F., additional, Anolli, M.P., additional, Lampertico, P., additional, Craxì, A., additional, Di Marco, V., additional, and Cammà, C., additional

Published
2023
Full Text
View/download PDF

44. Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di)

Author

Anolli, M.P., primary, Degasperi, E., additional, D'Offizi, G., additional, Brunetto, M.R., additional, Verucchi, G., additional, Federico, A., additional, Ciancio, A., additional, Mangia, A., additional, Santantonio, T.A., additional, Coppola, N., additional, Pellicelli, A., additional, Loglio, A., additional, Viganò, M., additional, Pileri, F., additional, Maracci, Monia, additional, Puoti, M., additional, Piscaglia, F., additional, and Lampertico, P., additional

Published
2023
Full Text
View/download PDF

45. Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

Author

Buti, M., primary, Wedemeyer, H., additional, Aleman, S., additional, Chulanov, V., additional, Morozov, V., additional, Sagalova, O., additional, Stepanova, T., additional, Gish, R. G, additional, Lloyd, A., additional, Kaushik, A. M, additional, Suri, V., additional, Manuilov, D., additional, Osinusi, A. O, additional, Flaherty, J., additional, Pandey, S., additional, Singh, B., additional, and Lampertico, P., additional

Published
2023
Full Text
View/download PDF

46. Improvement of clinical parameters in HDV patients with advanced compensated cirrhosis treated with Bulevirtide monotherapy for 48 weeks

Author

Degasperi, E., primary, Anolli, M.P., additional, Renteria, S.C. Uceda, additional, Sambarino, D., additional, Borghi, M., additional, Perbellini, R., additional, Facchetti, F., additional, Loglio, A., additional, Monico, Sara, additional, Fraquelli, M., additional, Costantino, A., additional, Ceriotti, F., additional, and Lampertico, P., additional

Published
2023
Full Text
View/download PDF

47. Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis

Author

Lampertico, P., primary, Aleman, S., additional, Blank, A., additional, Bogomolov, P., additional, Chulanov, V., additional, Mamonova, N., additional, Morozov, V., additional, Sagalova, O., additional, Stepanova, T., additional, Suri, V., additional, Manuilov, D., additional, Ye, L., additional, Flaherty, J.F., additional, Osinusi, A., additional, Cornberg, M., additional, Brunetto, M., additional, and Wedemeyer, H., additional

Published
2023
Full Text
View/download PDF

48. OC.12.2 RESIST CRITERIA: A BIOCHEMICAL ALGORITHM TO REDUCE THE NUMBER OF UNNECESSARY UPPER ENDOSCOPIES FOR THE EVALUATION OF PORTAL HYPERTENSION IN COMPENSATED HBVCIRRHOTIC PATIENTS

Author

Calvaruso, V., primary, Celsa, C., additional, Degasperi, E., additional, Di Maria, G., additional, Fichera, A., additional, Graceffa, P., additional, Rancatore, G., additional, Falco, G., additional, Di Martino, V., additional, Rizzo, G.E.M., additional, Grasso, M., additional, Simone, F., additional, Anolli, M., additional, Lampertico, P., additional, Craxi, A., additional, Di Marco, V., additional, and Camma, C., additional

Published
2023
Full Text
View/download PDF

49. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B

Author

Vecchi, Andrea, Rossi, Marzia, Tiezzi, Camilla, Fisicaro, Paola, Doselli, Sara, Gabor, Elena Adelina, Penna, Amalia, Montali, Ilaria, Ceccatelli Berti, Camilla, Reverberi, Valentina, Montali, Anna, Fletcher, Simon P, Degasperi, Elisabetta, Sambarino, Dana, Laccabue, Diletta, Facchetti, Floriana, Schivazappa, Simona, Loggi, Elisabetta, Coco, Barbara, Cavallone, Daniela, Rosselli Del Turco, Elena, Massari, Marco, Pedrazzi, Giuseppe, Missale, Gabriele, Verucchi, Gabriella, Andreone, Pietro, Brunetto, Maurizia Rossana, Lampertico, Pietro, Ferrari, Carlo, and Boni, Carolina

Abstract

ObjectiveSelected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim of our study was to assess the immunomodulatory effect of pegIFN-α on T and natural killer (NK) cell responses in NUC-suppressed patients to identify cellular and/or serological parameters to predict better T cell-restoring effect and better control of infection in response to pegIFN-α for a tailored application of IFN-α add-on.Design53 HBeAg-negative NUC-treated patients with CHB were randomised at a 1:1 ratio to receive pegIFN-α-2a for 48 weeks, or to continue NUC therapy and then followed up for at least 6 months maintaining NUCs. Serum hepatitis B surface antigen (HBsAg) and hepatitis B core‐related antigen (HBcrAg) levels as well as peripheral blood NK cell phenotype and function and HBV-specific T cell responses upon in vitro stimulation with overlapping HBV peptides were measured longitudinally before, during and after pegIFN-α therapy.ResultsTwo cohorts of pegIFN-α treated patients were identified according to HBsAg decline greater or less than 0.5 log at week 24 post-treatment. PegIFN-α add-on did not significantly improve HBV-specific T cell responses during therapy but elicited a significant multispecific and polyfunctional T cell improvement at week 24 post-pegIFN-α treatment compared with baseline. This improvement was maximal in patients who had a higher drop in serum HBsAg levels and a lower basal HBcrAg values.ConclusionsPegIFN-α treatment can induce greater functional T cell improvement and HBsAg decline in patients with lower baseline HBcrAg levels. Thus, HBcrAg may represent an easily and reliably applicable parameter to select patients who are more likely to achieve better response to pegIFN-α add-on to virally suppressed patients.

Published
2024
Full Text
View/download PDF

50. Advances in hepatitis delta research: emerging insights and future directions

Author

Degasperi, Elisabetta, Anolli, Maria Paola, and Lampertico, Pietro

Abstract

ObjectivesHepatitis delta virus (HDV) is a defective virus needing the envelope provided by hepatitis B virus (HBV) in order to enter liver cells and propagate. Chronic HDV infection is considered the most severe viral hepatitis, resulting in accelerated fibrosis progression until cirrhosis and its complications (hepatocellular carcinoma, liver decompensation) compared with HBV mono-infected patients. Off-label treatment with interferon has represented the only treatment option in the last 40 years, resulting in suboptimal virological response rates and being limited by safety issues especially in patients with advanced cirrhosis. Recently, the first HBV-HDV entry inhibitor Bulevirtide (BLV) has been approved by the European Medicines Agency (EMA) for treatment of chronic compensated HDV.MethodsThis review summarises most recent updates on HDV epidemiology, diagnosis and treatment, with a special focus both on clinical trials and real-life studies about BLV. An overview on new HDV compounds under development is also provided.ResultsBLV, the HBV-HDV entry inhibitor, has shown promising safety and efficacy data in clinical trials and in real-life studies, also in patients with advanced cirrhosis and portal hypertension. However, according to EMA label treatment is currently intended long-term until clinical benefit and predictors of responses are still undefined. The potential combination with PegIFNα seems to increase virological and clinical responses. New compounds are under development or in pipeline for treatment of HDV.ConclusionAfter more than 40 years since HDV discovery, new treatment options are currently available to provide efficient strategies for chronic hepatitis Delta.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results